




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/31, 15/62, C07K 14/22, 19/00, A61K 39/095</p>	A2	<p>(11) International Publication Number: WO 99/55875</p> <p>(43) International Publication Date: 4 November 1999 (04.11.99)</p>
<p>(21) International Application Number: PCT/US99/09486</p> <p>(22) International Filing Date: 29 April 1999 (29.04.99)</p> <p>(30) Priority Data: 60/083,405 29 April 1998 (29.04.98) US</p> <p>(71) Applicant (for all designated States except US): AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): METCALF, Thomas, N., III [US/US]; 10 Caywood Lane, Fairport, NY 14450 (US). ZAGURSKY, Robert, J. [US/US]; 569 Fox Hunt Drive, Victor, NY 14564 (US). OOI, Peggy [US/US]; 494 Main Street Fishers, Mendon, NY 14506 (US).</p> <p>(74) Agents: GORDON, Alan, M.; American Home Products Corporation, Patent Law Dept. - 2B2, One Campus Drive, Parsippany, NJ 07054 (US) et al.</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: VACCINES CONTAINING RECOMBINANT PILIN AGAINST <i>NEISSERIA GONORRHOEAE</i> OR <i>NEISSERIA MENINGITIDIS</i></p>		
		
<p>(57) Abstract</p> <p>The <i>pilE</i> genes of each of <i>Neisseria gonorrhoeae</i> and <i>Neisseria meningitidis</i> are cloned and their corresponding recombinant pilin proteins are expressed. In addition, a chimeric <i>pilE</i> gene is constructed in which the region of the <i>pilE</i> gene of <i>Neisseria meningitidis</i> class I encoding the amino-terminal region of the pilin protein is replaced by the corresponding region of the <i>pilE</i> gene of <i>Neisseria gonorrhoeae</i>. The recombinant meningococcal chimeric class I pilin protein is expressed at higher levels than the pilin protein expressed by the full-length <i>pilE</i> gene of <i>Neisseria meningitidis</i>. Furthermore, a chimeric <i>pilE</i> gene is constructed in which the region of the <i>pilE</i> gene of <i>Neisseria meningitidis</i> class II encoding the carboxy-terminal region of the pilin protein is replaced by the corresponding region of the <i>pilE</i> gene of <i>Neisseria gonorrhoeae</i>. The recombinant pilin proteins are used in vaccines to protect against disease caused by <i>Neisseria gonorrhoeae</i> or <i>Neisseria meningitidis</i>.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

VACCINES CONTAINING RECOMBINANT PILIN AGAINST
NEISSERIA GONORRHOEAE OR *NEISSERIA MENINGITIDIS*

Field of the Invention

5
This invention relates to the use of recombinant pilin proteins in vaccines to protect against disease caused by *Neisseria gonorrhoeae* or *Neisseria meningitidis*.

10
Background of the Invention

15
20
Neisseria gonorrhoeae (*N. gonorrhoeae*) and *Neisseria meningitidis* (*N. meningitidis*) are Gram-negative cocci. *N. gonorrhoeae* and *N. meningitidis* are genetically very closely related, but the clinical manifestations of the diseases they produce are very different. *N. gonorrhoeae* causes gonorrhea, while *N. meningitidis* causes meningococcal meningitis. These bacteria of the genus *Neisseria* inhabit mucosal surfaces of the body.

25
30
35
Type IV pili are nonflagellar hairlike structures on the surface of numerous Gram-negative bacteria, including *Dichelobacter* (formerly *Bacteroides*) *nodous*, *Eikenella corrodens*, *Kingella denitrificans*, *Moraxella bovis*, *M. lacunata*, *M. nonliquefaciens*, *N. gonorrhoeae*, *N. meningitidis*, and *Pseudomonas aeruginosa* (Bibliography Entries 1,2). The toxin co-regulated pili from *Vibrio cholerae* and the bundle forming pili of enteropathogenic *Escherchia coli* exhibit a limited number of similarities to type IV pili and are considered to be more distantly related (1,2). For both *N. gonorrhoeae* and *N. meningitidis*, piliated bacteria adhere to a variety of epithelial cells of human origin much more avidly than do

- 2 -

nonpiliated cells, and thus the pili are thought to act as virulence factors by anchoring the organisms to mucosal infection sites.

5 Type IV pili are 5-7 nM in width and up to 5 μ M in length. The pilin protein subunits are linked in tandem to form long, thin polymers. In the case of the pathogenic *Neisseria*, the pili are apparently homopolymeric in nature, being comprised of a single structural subunit, the pilin protein. The pilin
10 protein has a molecular weight of 13,000 to 22,000 daltons (1,2,3).

In nature, the pilin protein is assembled into a helical structure called a pilus (plural: pili) at the bacterial outer membrane that has a molecular
15 weight of approximately 10^7 daltons. When purified pili are dialyzed against pH 12 phosphate buffer, the intact pili are irreversibly dissociated into aggregates of the pilin protein which are called pilin oligomers (4). These pilin oligomer aggregates
20 (molecular weight of approximately 600,000 daltons) are much smaller in size than the intact pilus.

N. gonorrhoeae expresses a single pilin protein which was first isolated and sequenced by Schoolnik and co-workers (5). The gonococcal pilin
25 protein consists of three regions: (a) the highly conserved amino terminal region (residues 1-53); (b) the middle third (residues 54-124) which exhibits a limited amount of sequence variation and (c) the carboxy third of the protein (residues 125-160) which
30 contains a highly variable disulfide loop.

During the course of natural infections, pili undergo high frequency phase and antigenic variation (3,6). The genetics of this variation are
35 extraordinarily complex and have been extensively studied. Each strain of *Neisseria gonorrhoeae* has the

- 3 -

ability to change the primary amino acid sequence of the pilin molecule, and thus the antigenic nature of its pili. The molecular mechanism responsible for this variation involves a nonreciprocal recombination event
5 between the expression locus (*pilE*) and numerous (17 to 19), promoterless, silent (*pilS*) genes (6). Pilin sequences (or portions thereof) move from the *pilS* loci into an expression locus to generate new pilin variants, which in turn enables gonococci to express an
10 extremely large number of pilin proteins.

In contrast to *N. gonorrhoeae*, *N. meningitidis* expresses two distinct classes of pilin named class I and class II. As in the gonococci, the meningococcal class I pili undergo antigenic and phase
15 variation (3). Class I pilins have been shown to be similar to gonococcal pilin in terms of molecular weight (17-20 kd) and reactivity with a monoclonal antibody (SM1) which binds to a highly conserved epitope on the gonococcal pilin (3). A number of
20 class I pilins have been cloned and the amino acid sequences have been shown to have a high degree of similarity to the sequence of the gonococcal pilin (7). In contrast, class II pilins do not react with the SM1 antibody and have a lower molecular weight (13-16 kd).
25 Several strains expressing class II pilin have been shown to react with a polyclonal antisera directed against gonococcal pili (3). Aho et al. (7) have recently determined the sequence of a class II pilin. The first third of the neisserial pilins are
30 essentially identical. The class II pilin protein differs from the class I pilin and gonococcal pilin proteins in the hypervariable region of the protein where a large deletion has occurred. Achtman et al. (8), using monoclonal antibodies specific for class I
35 or class II pilins, demonstrated that some serogroup A

- 4 -

isolates from Africa bound both antibodies. It has been demonstrated that strains expressing class II pili also have truncated, silent class I pilin genes (7). Taken together, these data suggest the possibility that a single meningococcal cell might express both pilin proteins simultaneously.

Because pili are believed to mediate the initial contact with mucosal cells, there has been considerable interest in using these structures as vaccine antigens to prevent disease caused by piliated bacteria. Pili vaccines against traveler's diarrhea and gonorrhoea have been tested in human beings (9). However, to date, they have been efficacious only against homologous strains. A number of pili-based vaccines have been reported for diseases affecting domestic livestock such as infectious keratoconjunctivitis (pinkeye) in cattle (1), footrot in sheep (1,10) and diarrhea in piglets (9) or calves (9). In each of these veterinary examples, the pili vaccine provided protection against challenge by strains expressing the homologous, but not heterologous, pili.

The earliest gonococcal vaccines contained whole organisms and provided little or no protection (11). Recent vaccine development against gonorrhoea has focused on purified surface components, in particular, pili (9,11) and the porin protein (P.I or Por) (11). To date, however, only pili have been shown to protect humans from challenge, and this was limited to protection against the homologous strain (12). A denatured form of gonococcal pili (4) has been shown to generate antibodies in mice or guinea pigs which bind to heterologous pili *in vitro*. However, this has not been considered a commercially viable approach because of the difficulty in growing piliated gonococci in

- 5 -

liquid media (a necessity for commercial production)
(1). Based on the success of the initial human
challenge studies, the gonococcal pilus vaccine was
tested in a large, placebo-controlled double blind
5 efficacy trial (12). In this trial, the vaccine failed
to protect male volunteers from gonococcal infections.
It was postulated that the most likely explanation for
this was pilus heterogeneity (12).

10 Indeed, the antigenic variability of the
pilin proteins, both gonococcal and meningococcal, has
been repeatedly cited as a major obstacle in the
development of pili-based vaccines (3,13,14,15,16,17).
It has been suggested that the dominant immune epitope
on the assembled, intact pilus is the disulfide loop,
15 which exhibits the greatest sequence variation (17,18).
This may account for the failure of the Korean field
trial with formalin-treated intact pili from *N.*
gonorrhoeae strain Pgh3-2 (12). In addition, the
literature contains a number of references in which
20 antisera directed against purified pili, or pilin
fragments, bound to denatured (Western blot) or
isolated neisserial pili, but did not bind to
heterologous pili on bacterial surfaces (16,17,19,20).
Whether this is due to antigenic variation or
25 concealment of the epitopes in the assembled pilus has
not been completely resolved. This is reinforced by
several reports which demonstrated that the only
monoclonal antibodies exhibiting functional activity *in*
vitro were those which did not bind to heterologous
30 pili (3). It has been shown for the intact pili from
M. bovis (21) and *D. nodosus* that a protective immune
response elicited by pili is possible (10). These
vaccines, however, were only able to protect against
challenge with bacteria expressing the homologous pili
35 -- not heterologous pili (10,21). The consensus of the

- 6 -

scientific community appears to be that pili-based vaccines, if possible, will protect only against bacteria expressing the homologous pili.

5 Recombinant expression of assembled pili has been described for a number of organisms, and is dependent on the presence of appropriate transport and assembly genes (22). In *Neisseria*, the genes encoding the proteins involved in pili assembly and export are not found in a single contiguous operon, so this
10 approach was not feasible. Another alternative chosen in European Patent 202,260 B1 was to express type IV pilin genes in a bacterial host which already possessed the proteins required for assembly of a different type IV pilus; e.g., *Pseudomonas aeruginosa* (23). But as
15 reported by Hoyne et al., the expression and assembly of gonococcal pili at the outer membrane of *Pseudomonas* was unstable (24). When the recombinant strain was grown in liquid media in the presence of selective antibiotics, it was overgrown by wild-type, pilated
20 *Pseudomonas*. The authors stated:

"[T]he compatibility of foreign mePhe [N-methylphenylalanine] pilus production in host strains will depend on the extent of divergence of host and donor pilus assembly systems. The
25 observed instability of PAK/2PfS [*Pseudomonas aeruginosa* strain K/2PfS] expressing gonococcal pilin ... may indicate that the limits of interspecies expression of mePhe pili are being approached in this instance." (24)

30 Because of this result, the expression of gonococcal pili in *Pseudomonas* was not viewed as a commercially viable approach.

35 Elleman, Egerton and co-workers described the development of a vaccine against ovine footrot using intact pili from *Dichelobacter nodosus*. Field trials

- 7 -

had demonstrated that intact pili protected against *D. nodosus* strains expressing the homologous pili. This meant that a commercial vaccine would need to contain eight or nine different pili in order to achieve comprehensive protection. In an attempt to make this approach viable, the pilin gene of *D. nodosus* was cloned and expressed in *E. coli* (25). The recombinant pilin protein was found associated with the inner membrane. When a vaccine consisting of sonicated *E. coli* cells expressing the recombinant pilin was tested in a challenge experiment, the recombinant *E. coli* cells generated an antibody titer similar to that seen for purified, native pili (25). However, the agglutination titer induced by the recombinant *E. coli* cell vaccine was significantly lower than that seen for the intact pili (690 vs. 47,800) and below the titer which correlated with protection (5,000-10,000) (25,26).

Following active challenge with *D. nodosus*, the recombinant pilin vaccine failed to show any significant protective activity, in contrast to that seen for the intact pili. Emery and co-workers had demonstrated that denaturation of intact pili abolished the ability of pilin to induce protection in animals (27). In addition, pili dissociated with either detergent (octyl- β -D-glucoside) or low pH (2.2) reduced the effectiveness of the protein to elicit protection against formation of severe lesions following challenge (28). This was despite the fact that the antibody titers were not significantly different between the groups. The authors stated that "there may be one or more epitopes associated with quaternary structure which are disturbed by the treatments". They further stated:

- 8 -

5 "The failure of the *E. coli* expressed product
as a vaccine may result from its physical
occlusion in the host cell membranes, although
preliminary experiments indicated that this was
not the major cause of its ineffectiveness
(unpublished data). An alternative explanation
for the failure of the *E. coli* expressed
product as a vaccine, is that the monomeric
prepilin units which are expressed are unable
10 to associate into a native conformation for the
appropriate presentation of important epitopes,
possibly because of the presence of the leader
sequence." (28).

15 Elleman and co-workers confirmed the importance of the
presence of conformational epitopes on the recombinant
pilin and that they needed to increase the immune
response by a better presentation of the antigen. They
proposed two approaches: purification of the protein
from the *E. coli* membranes, or expression of protein in
20 *P. aeruginosa* so that it could assemble into
filamentous pili on the surface of the cell. The
latter approach was preferred because "[t]his should
greatly improve the immunogenic properties and simplify
the purification of the protein" (25).

25 Furthermore, Elleman and co-workers also
viewed the use of pilin (the subunit protein of pili)
as an inferior vaccine candidate to the mature fimbriae
(intact pili) for *D. nodosus*:

30 "Mature fimbriae appear to provoke a more intense
and appropriate (*i.e.*, K-agglutinating)
immunological reaction than the equivalent dose of
fimbrial subunit protein. A serological K-
agglutination titre of about 5,000 is generally
regarded as the minimum response commensurate with
35 adequate protective immunity against infection

- 9 -

with a given strain of *B. nodosus*. This level of response (and up to an order of magnitude higher) is readily achieved upon vaccination with mature fimbriae, but not the isolated subunit protein, which elicits only poor levels of serum K-agglutinating antibodies" (23).

Additional data suggesting that the fimbrial (pilus) subunit protein is not a viable vaccine candidate was recently reported by Alves et al. (29). When mice were immunized with a polynucleotide vaccine encoding the *E. coli* CFA/I fimbrial adhesin protein (e.g., pilin), the antibodies induced were distinct from those induced by native, intact CFA/I fimbriae. Moreover, these antibodies against the recombinant protein did not exhibit any agglutination activities in contrast to antisera against the native protein.

Despite all the work described above, there is yet to be developed an effective pilus-based gonococcal or meningococcal vaccine. Meningococcal vaccines are limited to those possessing serotype A, C, Y, W135 capsules.

Accordingly, there is a need to identify components for inclusion in vaccines to protect against disease caused by *N. gonorrhoeae* or all serotypes of *N. meningitidis*.

Summary of the Invention

Thus, it is an object of this invention to identify suitable antigenic structures derived from *N. gonorrhoeae* and *N. meningitidis*, respectively, which may constitute viable vaccine candidates against those bacteria. These candidates must induce antibodies which recognize and bind to diverse isolates of the respective pathogenic neisserial organism.

- 10 -

These and other objects of the invention as discussed below are achieved by the cloning and expression of the recombinant pilin protein (rpilin) of each of *N. gonorrhoeae* and *N. meningitidis*.

5 This invention also relates to the construction of a plasmid which expresses a recombinant meningococcal chimeric class I pilin protein in which the amino-terminal region of the class I meningococcal pilin protein is replaced by the corresponding amino-
10 terminal region of the gonococcal pilin protein. This plasmid expresses significantly higher amounts of the meningococcal chimeric class I rpilin protein than the class I meningococcal rpilin protein expressed from a full-length meningococcal *pilE* gene.

15 In order to obtain expression of the meningococcal chimeric class I rpilin protein, the chimeric DNA sequence is first inserted into a suitable plasmid vector. A suitable host cell is then transformed or transfected with the plasmid. In an
20 embodiment of this invention, the host cell is an *Escherichia coli* strain. The host cell is then cultured under conditions which permit the expression of said chimeric class I rpilin protein by the host cell.

25 This invention further relates to the construction of a plasmid which expresses a recombinant meningococcal chimeric class II pilin protein in which the carboxy-terminal region of the class II meningococcal pilin protein is replaced by the
30 corresponding carboxy-terminal region of the gonococcal pilin protein.

In order to obtain expression of the meningococcal chimeric class II rpilin protein, the chimeric DNA sequence is first inserted into a suitable
35 plasmid vector. A suitable host cell is then

- 11 -

transformed or transfected with the plasmid. In an embodiment of this invention, the host cell is an *Escherichia coli* strain. The host cell is then cultured under conditions which permit the expression of said chimeric class II rpilin protein by the host cell.

In another embodiment of this invention, the isolated and purified rpilin protein (either the gonococcal, the meningococcal or chimerics) is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host. The vaccine composition may further comprise an adjuvant, diluent or carrier. Examples of such adjuvants include aluminum hydroxide, aluminum phosphate, MPL™, Stimulon™ QS-21, IL-12 and cholera toxin. The vaccine composition is administered to a mammalian host in an immunogenic amount sufficient to protect the host against disease caused by *N. gonorrhoeae* or *N. meningitidis*.

Brief Description of the Figures

Figure 1 depicts transmission electron micrographs of piliated cells from *N. gonorrhoeae* (strain I756 recA-) incubated with guinea pig antisera directed against gonococcal rpilin (from strain Pgh3-1) (1:50 dilution for 15 minutes), followed by donkey anti-guinea pig IgG conjugated to 12 nm colloidal gold (1:5 dilution for 30 minutes and stained with NanoVan. Figure 1A depicts anti-rpilin guinea pig immune sera (week 6); Figure 1B depicts normal guinea pig sera (week 0); Figure 2C depicts no primary antibody.

Figure 2 depicts the effect of guinea pig antisera directed against gonococcal rpilin (from strain Pgh3-1) on the attachment of piliated *N.*

- 12 -

gonorrhoeae cells (strain I756 recA-) to human cervical cells (ME180 cell line). Figure 2A depicts the inhibition of attachment by guinea pig antisera directed against rpilin (week 6); Figure 2B depicts the inability of normal guinea pig antisera to prevent attachment of piliated gonococcal cells to cervical cells (week 0). Representative sized clumps of bacteria bound to cervical cells are circled in each panel. Each panel shows four different views of the same experimental condition. The guinea pig antisera was diluted 1:10,000 for each panel.

Figure 3 depicts transmission electron micrographs of piliated cells from *N. meningitidis* (strain H355) incubated with guinea pig antisera directed against meningococcal chimeric class I rpilin (from strain H44/76) (1:60 dilution for 30 minutes), followed by donkey anti-guinea pig IgG conjugated to 12 nm colloidal gold (1:5 dilution for 30 minutes) and stained with NanoVan. Figure 3A depicts anti-rpilin guinea pig immune sera (week 6); Figure 3B depicts normal guinea pig sera (week 0); Figure 3C depicts no primary antibody. Cells were fixed before being incubated with antisera.

Detailed Description of the Invention

This invention relates to vaccine compositions comprising a recombinant pilin protein of *N. gonorrhoeae* or *N. meningitidis*. Notwithstanding the teachings of the art discussed above, it was decided to investigate the use of such recombinant pilin proteins expressed in *E. coli*. Surprisingly, these recombinant pilin proteins demonstrated characteristics of vaccine candidates.

- 13 -

The first report describing the cloning of the gonococcal *pilE* gene in *E. coli* was in 1982 (30). Since then, molecular characterization of *pilE* has been performed by numerous laboratories investigating the genetic factors controlling the expression of the pilin protein, transport of the pilin protein, variation in the pilin sequence and the host adherence properties of pili. However, none of the reports described the purification of recombinant pilin protein nor the immune response of the recombinantly expressed pilin protein.

Cloning and expression of the *pilE* gene encoding the gonococcal recombinant pilin protein are described in Example 2 below. Expression was achieved by transforming an *E. coli* strain designated TOP10F' with a plasmid containing the *pilE* gene. Successful cloning and expression was followed by the sequencing of the *pilE* gene to confirm identity with the native sequence. To assist in cloning, a *NcoI* site was introduced, which required modifying one base. As a result, the second amino acid in the seven amino acid long signal peptide was changed from asparagine to aspartic acid.

The plasmid containing the *pilE* gene in Example 2 (designated pPX2000) contains an ampicillin resistance (Amp^{R}) marker. As described in Example 3, another plasmid was constructed to contain a kanamycin resistance (Kan^{R}) marker instead of Amp^{R} . This plasmid, designated pPX2002, after transforming *E. coli* strain TOP10F', expressed the gonococcal rpilin at a level similar to that obtained from pPX2000, which contains an Amp^{R} marker.

As described in Example 4, a similar procedure was used to construct a plasmid, designated pPX2003, containing the class I *pilE* gene of *N.*

- 14 -

meningitidis. A *Nco*I site (CC ATG G) was introduced spanning the beginning of the gene encoding the signal peptide. This changed the second amino acid residue of the signal peptide from asparagine to aspartic acid (the first residue remained methionine). An Amp^R marker was also included. This construct, after transforming *E. coli* strain TOP10F', expressed class I rpilin of *N. meningitidis*. However, the expression level was significantly lower than that for the gonococcal rpilin obtained from either pPX2000 or pPX2002. Without being bound by theory, this lower expression level may be due to a number of inverted repeats which are present in the recombinant class I *pile*.

In order to increase the expression of the meningococcal pilin, as described in Example 5, a chimeric plasmid was constructed. The DNA in pPX2003 encoding the first 60 amino acids of the meningococcal class I rpilin is replaced with the equivalent region from the gonococcal DNA in pPX2002. The resulting Amp^R plasmid, designated pPX2004, has the nucleotide sequence set forth in SEQ ID NO:1. The plasmid pPX2004 was used to transform an *E. coli* strain K12 designated TOP10F'. Following induction, there was a significant increase in expression of the chimeric rpilin compared to the amount of meningococcal rpilin expressed from pPX2003. The level of expression of the chimieric construct was comparable to the amount of gonococcal rpilin expressed from pPX2002. The chimeric class I rpilin was 167 amino acids in length (including the signal) (SEQ ID NO:2), which is in accordance with the predicted size.

Samples of the *E. coli* strain K12 designated TOP10F' harboring the recombinant plasmid pPX2004 were deposited on January 27, 1998 by the Applicants with

- 15 -

the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., and have been assigned ATCC accession number ATCC 98637.

As described in Example 6, a chimeric plasmid was constructed wherein the 3' end of the class II *pile* gene of *N. meningitidis* was replaced with the corresponding region from *N. gonorrhoeae*.

Specifically, the DNA in pPX8001 encoding the disulfide loop (the last 22 amino acids of the meningococcal class II pilin of *N. meningitidis* strain FAM18) is replaced with a similiar (but larger) region plus additional portions of the carboxy-terminal region totalling 44 amino acids from the gonococcal (*pile*) DNA from *N. gonorrhoeae* strain Pgh3-1 in pPX2000. The resulting Amp^R plasmid, designated pPX8017, has the nucleotide sequence set forth in SEQ ID NO:3, in which nucleotides 1-378 are from *N. meningitidis* class II and nucleotides 379-510 are from *N. gonorrhoeae*. The plasmid pPX8017 was used to transform the *E. coli* strain K12 designated TOP10F'. Following induction, a chimeric class II rpilin was expressed which was 170 amino acids in length (including the seven amino acid long signal) (SEQ ID NO:4), in which amino acids 1-126 are from *N. meningitidis* class II and amino acids 127-170 are from *N. gonorrhoeae*. This chimeric class II rpilin was in accordance with the predicted size. A *Nco*I site was introduced for cloning considerations, which changed the second amino acid in the signal sequence from lysine to glutamic acid. This change was not expected to have any effect on antigenicity or immunogenicity.

Samples of the *E. coli* strain K12 designated TOP10F' harboring the recombinant plasmid pPX8017 were deposited on April 15, 1999 by the Applicants with the American Type Culture Collection, 10801 University

- 16 -

Boulevard, Manassas, Virginia 20110-2209, U.S.A., and have been assigned ATCC accession number ATCC 207199.

A variety of host cell-vector systems are suitable for use to express the gonococcal, meningococcal and chimeric rpilins used in the vaccines of this invention in addition to those detailed in Examples 2-6. The vector system is compatible with the host cell used. Suitable host cells include bacteria transformed with plasmid DNA, cosmid DNA or bacteriophage DNA; viruses such as vaccinia virus and adenovirus; yeast such as *Pichia* cells; insect cells such as Sf9 or Sf21 cells; or mammalian cell lines such as Chinese hamster ovary cells; as well as other conventional organisms.

A variety of conventional transcriptional and translational elements can be used for the host cell-vector system. The *pilE* DNA is inserted into an expression system and the promoter and other control elements are ligated into specific sites within the vector, so that when the plasmid vector is inserted into a host cell, the *pilE* DNA can be expressed by the host cell.

The plasmid is introduced into the host cell by transformation, transduction, transfection or infection, depending on the host cell-vector system used. The host cell is then cultured under conditions which permit expression of the rpilin protein by the host cell.

This invention further relates to an isolated and purified DNA sequence comprising a DNA sequence encoding the meningococcal chimeric class I rpilin protein whose amino-terminal region is from the gonococcal *pilE* gene and whose central and carboxy-terminal regions are from the meningococcal *pilE* gene (SEQ ID NO:1). Nucleotides 1-501 in SEQ ID NO:1 encode

- 17 -

the meningococcal chimeric class I rpilin protein prior to processing; nucleotides 22-501 encode the meningococcal chimeric class I rpilin protein after processing to a mature protein. The invention
5 additionally relates to the meningococcal chimeric class I rpilin protein having the amino acid sequence of amino acids 1-167 of SEQ ID NO:2 prior to processing or having the amino acid sequence of amino acids 8-167 of SEQ ID NO:2 after processing to a mature protein.
10 Approximately 10% of the total protein produced by the gonococcal rpilin or the meningococcal chimeric class I rpilin constructs lacks the signal sequence, which has been removed by processing.

This invention further relates to an isolated
15 and purified DNA sequence comprising a DNA sequence encoding the meningococcal chimeric class II rpilin protein whose carboxy-terminal region is from the gonococcal *pilE* gene and whose central and amino-terminal regions are from the meningococcal *pilE* gene
20 (SEQ ID NO:3). Nucleotides 1-510 in SEQ ID NO:3 encode the meningococcal chimeric class II rpilin protein prior to processing; nucleotides 22-510 encode the meningococcal chimeric class II rpilin protein after processing to a mature protein. The invention
25 additionally relates to the meningococcal chimeric class II rpilin protein having the amino acid sequence of amino acids 1-170 of SEQ ID NO:4 prior to processing or having the amino acid sequence of amino acids 8-170 of SEQ ID NO:4 after processing to a mature protein.

30 In addition to the chimeric DNA sequences contained in pPX2004 and pPX8017 which encode the meningococcal chimeric class I rpilin protein and the meningococcal chimeric class II rpilin protein, respectively, the present invention further comprises
35 DNA sequences which, by virtue of the redundancy of the

- 18 -

genetic code, are biologically equivalent to the sequences which encode for the chimeric rpilin proteins, that is, these other DNA sequences are characterized by nucleotide sequences which differ from those set forth herein, but which encode a protein having the same amino acid sequence as that encoded by the DNA sequence in SEQ ID NO:1 or SEQ ID NO:3.

In particular, the invention contemplates those DNA sequences which are sufficiently duplicative of the sequence of SEQ ID NO:1 or SEQ ID NO:3 so as to permit hybridization therewith under standard high stringency Southern hybridization conditions, such as those described in Sambrook et al. (31).

This invention also comprises DNA sequences which encode amino acid sequences which differ from those of the meningococcal chimeric class I or class II rpilin proteins, but which are biologically equivalent to those described for one of these proteins (SEQ ID NO:2 or SEQ ID NO:4). Such amino acid sequences may be said to be biologically equivalent to those of the chimeric rpilin protein if their sequences differ only by minor deletions from, insertions into or substitutions to the rpilin sequence, such that the tertiary configurations of the sequences are essentially unchanged from those of the rpilin protein.

For example, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, as well as changes based on similarities of residues in their hydrophobic index,

- 19 -

can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal or C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein.

Furthermore, changes in known variable regions are biologically equivalent where the tertiary configurations of the conserved regions are essentially unchanged from those of the rpilin protein. An alternative definition of a biologically equivalent sequence is one that is still capable of generating a cross-reactive immune response. In particular, the meningococcal chimeric class I and II recombinant pilins may be modified by lengthening or shortening the corresponding insertion from the gonococcal pilin, as long as the modified chimeric recombinant pilin is still capable of generating a cross-reactive immune response.

Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of structural and biological activity of the encoded products. Therefore, where the terms "meningococcal chimeric class I rpilin protein" or "meningococcal chimeric class II rpilin protein" are used in either the specification or the claims, it will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent protein.

As described in Example 7, the gonococcal rpilin protein is associated with cellular membranes of the *E. coli* used to express it. A variety of detergents are able to selectively solubilize the rpilin protein from *E. coli*, including Empigen™ BB, Triton™ X-100, reduced Triton™ X-100, octyl- β -D-glucopyranoside (OG), Zwittergent™ 3-10 or 3-14.

- 20 -

Following centrifugation, dialysis and fractionation on a column, the purified rpilin is obtained.

As described in Example 8, the chimeric class I rpilin was isolated and purified by disruption of *E. coli* cells, clarification by centrifugation, filtration, and fractionation on two columns.

As described in Example 9, the meningococcal chimeric class II rpilin was isolated and purified by disruption of *E. coli* cells, clarification by centrifugation, dialysis, and fractionation on two columns.

The purified gonococcal rpilin was subjected to repeated N-terminal sequencing as described in Example 10. Sequencing of the 20-40 amino-terminal residues gave results which agreed with the amino acid sequence deduced from the DNA sequence. The molecular weight of the rpilin (with signal) was determined to be 18,006 daltons by mass spectrometry, which compares well to the predicted mass of 17,981 daltons based on the amino acid content. In contrast, an apparent molecular weight of 68,899 daltons was obtained when the rpilin was subjected to size exclusion column chromatography using detergent. This suggested that the rpilin aggregated. Dialysis of the rpilin against PBS in an effort to remove detergent resulted in material having an apparent molecular weight of 452,349 daltons, as measured by gel filtration. This suggested that it had undergone further aggregation.

As detailed in Example 11, immune sera are obtained by immunizing guinea pigs or mice with the purified gonococcal rpilin. As set forth in Example 12, Western blot analysis showed that antisera against rpilin bound to whole cell lysates from piliated gonococcal cells, while there was no binding seen in non-piliated cell lysates. In contrast, antisera to

- 21 -

the pilin oligomer bound to both piliated and nonpiliated cell lysates.

As detailed in Example 13, when analyzed by ELISA, this pooled antisera against gonococcal rpilin had high endpoint titers for binding to purified gonococcal rpilin protein. Example 13 also details the effects of various adjuvants. When the rpilin was adjuvanted with either MPL™ alone, MPL™ plus aluminum phosphate, or Stimulon™ QS-21, good humoral immune responses in mice were obtained.

As set forth in Example 14, whole cell ELISA showed that antisera against rpilin bound to piliated cells, but not to isogenic non-piliated cells of a particular gonococcal strain.

As described in Example 15, mice were immunized intranasally with gonococcal rpilin with or without native cholera toxin. There was a significant immune response detected in the antigen ELISA from pooled sera generated after the mice were immunized with rpilin in the absence of adjuvant; this response was enhanced by the addition of native cholera toxin. The pooled sera had a low ELISA titer for binding to intact, piliated gonococcal cells; this binding was greatly enhanced when the mice were also immunized with native cholera toxin.

As described in Example 16, immunoelectron microscopy demonstrated that antibodies against rpilin were bound along the length of the pili filaments on the surface of gonococci. This suggested that the antibodies bound to epitopes which would be present on the surface of the bacteria *in vivo*.

Example 17 demonstrates the higher titers obtained for rpilin antisera binding to heterologous piliated bacterial isolates as compared to that obtained for antisera to recombinant pilin oligomer.

- 22 -

The rpilin is converted to rpilin oligomer by dialysis of the rpilin against pH 12 phosphate buffer.

Pili mediate the initial binding of *N. gonorrhoeae* to human mucosal cells. Therefore, if an antigen is able to elicit antibodies which inhibit the attachment of these bacteria to those cells, this would provide evidence that such an antigen is a vaccine candidate.

As discussed in Example 18, guinea pig antisera to rpilin significantly inhibited the binding of gonococci expressing heterologous pili to human cervical epithelial cells. Piliation of gonococci correlates with the infectivity of this bacterium (2,3,32).

These data indicate that the recombinant pilin was able to generate antibodies which bind to diverse pili on intact gonococcal cells and that the antisera exhibits a functional activity (inhibition of bacterial adherence) which would protect immunized human beings against gonococcal colonization and infection (32,33). It has been previously reported that immunization with *E. coli* cells which expressed recombinant pilin from *D. nodosus* were immunogenic (23,25,28), but not protective against challenge. Because of these results, these researchers turned away from the use of recombinant subunit pilin in favor of the assembled pilus. Yet, the data described herein suggest that, following purification, the recombinantly expressed pilin protein induces an immune response which should correlate with protection of humans from gonococcal colonization. Thus, these data support the view that rpilin is a viable vaccine candidate against *N. gonorrhoeae*.

As described in Example 19, the meningococcal chimeric class I rpilin protein was subjected to N-

- 23 -

terminal sequencing. Sequencing of the 35 amino-terminal residues gave results which agreed with the amino acid sequence deduced from the DNA sequence. The molecular weight of the chimeric rpilin (with signal) was determined to be 17,659 daltons by mass spectrometry, which compares well to the predicted mass of 17,676 daltons based on the amino acid content. In contrast, an apparent molecular weight of 69,480 daltons was obtained when the meningococcal chimeric class I rpilin protein was subjected to size exclusion column chromatography using detergent. As with the gonococcal rpilin, this suggested that the meningococcal chimeric class I rpilin protein aggregated.

As detailed in Example 20, when analyzed by ELISA, pooled antisera against the meningococcal chimeric class I rpilin protein had high endpoint titers to both meningococcal class I rpilin protein and to piliated meningococcal cells. As also detailed in Example 20, adjuvants, in particular Stimulon™ QS-21, generated significant responses for the binding of antisera against the meningococcal chimeric class I rpilin protein to both meningococcal class I rpilin protein and to piliated meningococcal cells.

As described in Example 21, immunoelectron microscopy demonstrated that antibodies against the meningococcal chimeric class I rpilin protein were bound along the length of the pili of meningococci. This suggested that the antibodies bound to epitopes which would be present on the surface of the bacteria *in vivo*.

In Example 4, it was shown that antisera directed against gonococcal rpilin recognized and bound to piliated meningococcal cells. In Example 22, it was shown that antisera raised against meningococcal

- 24 -

chimeric class I rpilin protein bound to piliated gonococcal cells.

As described in Example 23, passive immunization of infant rats with guinea pig antisera against meningococcal chimeric class I rpilin protein can help prevent meningococcal bacteremia *in vivo*. There was a significant decrease in the level of colonization in animals who received this immune sera. Furthermore, the immune response generated using recombinantly expressed pilin can protect, *in vivo*, against meningococci which express a heterologous pilin protein.

As described in Example 24, mice were immunized intranasally with meningococcal chimeric class I rpilin with or without cholera toxin, where the cholera toxin is in a mutant form wherein the glutamic acid at amino acid position 29 is replaced by a histidine (CT-CRM, E29H). There was a significant immune response detected in the antigen ELISA from pooled sera generated after the mice were immunized with rpilin in the absence of adjuvant; this response was enhanced by the addition of mutant CT-CRM, E29H cholera toxin.

As described in Example 25, the inhibition of colonization of mouse nasopharynx by a class I strain of *N. meningitidis* was demonstrated in mice immunized subcutaneously with meningococcal chimeric class I rpilin adjuvanted with MPL™.

As described in Example 26, Western blot analysis showed that antisera obtained from guinea pigs immunized with meningococcal chimeric class II rpilin bound to whole cell lysates from piliated meningococcal cells which expressed either class I or class II pilin.

As described in Example 27, antisera elicited against partially purified meningococcal chimeric class

- 25 -

II rpilin bound to meningococcal cells from the homologous bacterial strain.

Taken together, these data support the view that rpilin, in particular the meningococcal chimeric class I and class II rpilin proteins, are viable vaccine candidates against *N. meningitidis*.

The gonococcal rpilin protein is useful in the preparation of vaccines to confer protection to mammals against disease caused by *N. gonorrhoeae*. The meningococcal rpilin protein, the meningococcal chimeric class I rpilin protein and the meningococcal chimeric class II rpilin protein are useful in the preparation of vaccines to confer protection to mammals against disease caused by *N. meningitidis*.

In addition, cross-protection against a different *Neisseria* species is afforded by immunizing with a vaccine containing the gonococcal rpilin protein to confer protection to mammals against disease caused by *N. meningitidis* or by immunizing with a vaccine containing the meningococcal rpilin protein, the meningococcal chimeric class I rpilin protein or the meningococcal chimeric class II rpilin protein to confer protection to mammals against disease caused by *N. gonorrhoeae*.

These vaccine compositions comprise an isolated and purified rpilin protein, wherein the vaccine composition elicits a protective immune response in a mammalian host.

Vaccines containing a rpilin protein may be mixed with immunologically acceptable diluents or carriers in a conventional manner to prepare injectable liquid solutions or suspensions. The level of antibodies elicited by the vaccine may be improved by using certain adjuvants such as Stimulon™ QS-21 (Aquila Biopharmaceuticals, Inc., Framingham, MA), MPL™ (3-O-

- 26 -

deacylated monophosphoryl lipid A; RIBI ImmunoChem Research, Inc., Hamilton, MT), aluminum phosphate, aluminum hydroxide, IL-12 (Genetics Institute, Cambridge, MA) and cholera toxin (either in a wild-type
5 or mutant form, for example wherein the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with U.S. Provisional Patent Application Number 60/102,430).

The vaccines of this invention are
10 administered by injection in a conventional manner, such as subcutaneous, intraperitoneal or intramuscular injection into humans, as well as by oral, mucosal, intranasal or vaginal administration, to induce an active immune response for protection against disease
15 caused by *N. gonorrhoeae* or *N. meningitidis*. The dosage to be administered is determined by means known to those skilled in the art. Protection may be conferred by a single dose of vaccine, or may require the administration of several booster doses.

20 In order that this invention may be better understood, the following examples are set forth. The examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention.

Examples

25 Standard molecular biology techniques are utilized according to the protocols described in
30 Sambrook et al. (31).

35

Example 1
Bacteria and Cell Cultures

Bacteria and Culture Conditions

5 The gonococcal isolates were obtained from Tampa, FL; Ottawa, Canada; Washington, D.C.; Seattle, WA; Rochester, NY; Chapel Hill, NC; and Evanston, IL. The meningococcal isolates were obtained from Chapel Hill, NC; and Bilthoven, Netherlands.

10 The bacteria were stored in lyophilized form or frozen at -70°C until required. When grown on solid media, the agar plates were incubated in an incubator at 37°C containing a humidified atmosphere and 5% (v/v) CO₂. *N. gonorrhoeae* and *N. meningitidis* were grown on
15 GC medium base (Difco Laboratories, Detroit, MI) without hemoglobin, but supplemented with dextrose (400 mg/L), glutamine (10 mg/L), cocarboxylase (20 µg/L) and ferric nitrate (500 µg/L). Liquid suspension cultures of *N. meningitidis* were grown in the same media which
20 lacked agar in a shaking incubator (70 RPM) at 37°C. In experiments involving culturing of meningococci from mouse nasal tissue homogenates, the bacteria were grown on GC media described above with the following mixture of antibiotics (Difco): colistin sulfate (75 µg/mL),
25 nystatin (125 µg/mL), vancomycin (30 µg/mL) and trimethoprim lactate (50 µg/mL). Piliated gonococci were identified by colony morphology and individual colonies passaged daily in order to maintain the phenotype. The piliation state of meningococcal cells
30 was assessed by transmission electron microscopic examination of samples stained with NanoVan stain (Nanoprobe, Stony Brook, NY) at pH 8 for 30 seconds. *E. coli* were grown on SOB agar which consists of 20 g/L Bacto tryptone (Difco), 5 g/L yeast extract (Difco),
35 0.6 g/L NaCl, 0.2 g/L KCl and 1% (w/v) agar (pH 7.5) or

- 28 -

in SOB broth to which the agar is not added. For some experiments, the Bacto tryptone was replaced with an equivalent amount of HySoy™ (Sheffield Products, Norwich, NY).

5

Epithelial cell cultures

ME-180 cell line (ATCC, Beltsville, MD) is an epidermoid carcinoma which was originally derived from a cervical carcinoma. The cells were grown in RPMI 1640 (Gibco BRL, Gaithersburg, MD) supplemented with 10% (v/v) fetal calf serum (Sigma, St. Louis, MO), penicillin G (1000 units/mL) (Gibco BRL), L-streptomycin (1 mg/mL) (Gibco BRL) and 2 mM L-glutamine in a humidified atmosphere of 5% (v/v) CO₂ at 37°C. The cells were split every three to four days.

10

15

Example 2

Cloning and Expression of Gonococcal *pile* in *E. coli*

20

25

30

35

A frozen sample of piliated *N. gonorrhoeae* strain Pgh3-1 was used as the source of the *pile* DNA in a PCR reaction. The *pile* gene was amplified using the following primers which recognized the 3' and 5' ends of the complete pilin protein (including the leader sequence): 5' CCC CGC GCC ATG GAT ACC CTT CAA AAA GGC 3' (PILEFWD) (SEQ ID NO:5) and 5' GGG CCT GGA TCC GTG GGA AAT CAC TTA CCG 3' (PILEREV) (SEQ ID NO:6). The resulting PCR product contained a *Nco*I site at the beginning of the *pile* coding region and a *Bam*HI site at the end. The *Nco*I site was introduced into the gene because of cloning considerations. This resulted in a change of the second amino acid in the signal sequence from asparagine (AAT) to aspartic acid (GAT). Because amino acid 2 is part of the signal peptide which is

- 29 -

cleaved during normal processing of the mature protein, this change was not expected to have any effect on antigenicity or immunogenicity. The PCR product was cloned into a pCR™II TA cloning vector (Invitrogen, Carlsbad, CA), ligated, and transformed into *E. coli* TOP10F' (Invitrogen). Colonies were selected on 100 µg/mL ampicillin containing plates or on 50 µg/mL kanamycin containing plates. The plasmid DNA was isolated from overnight cultures of these transformants and analyzed by restriction digests using the enzymes *EcoRI* and *NotI*.

Four clones containing an insert of the correct size were submitted for DNA sequence analysis in order to verify the presence of *pile* PCR DNA fragment. Clone #17, designated pPX1999, was used as the source of the *pile* gene. Plasmid DNAs from pPX1999 and pTrcHisA (Invitrogen) were digested with *NcoI* and *BamHI* restriction enzymes, the DNA fragments gel isolated, ligated and transformed into *E. coli* TOP10F'. Ampicillin resistant colonies were selected, the plasmid DNA of the new transformant isolated, and a DNA restriction analysis done using *BamHI* and *NcoI* restriction enzymes. Two clones with the correct restriction pattern were submitted for DNA sequence analysis. Both clones had the correct DNA sequence and were designated pPX2000.

To test for expression of the recombinant pilin, cultures containing these clones were grown in either shake flasks or a fermentor in SOB plus 100 µg/mL ampicillin and 12 µg/mL tetracycline. When shake flasks were used, *E. coli* were grown in 1L of media until an $A_{600} = 0.9-1.0$ was obtained. The expression of the recombinant pilin was induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and allowing growth to

- 30 -

continue for 1-4 hours, at which point the cells were collected by centrifugation (13,689 x g for 20 minutes at 4°C) and stored at -20°C. For the fermentor, an overnight culture from a plate was used to inoculate a flask containing 500 mL media which was again grown overnight. This liquid culture was then used to inoculate a Biostat B Fermentor (Braun Biotech, Allentown, PA) containing 8.9 L of media. Enhanced growth of the bacteria in the fermentor was obtained when HySoy™-containing media was supplemented with dextrose at a final concentration of 1% (w/v). When the culture reached $A_{600} = 1.0$, IPTG was added to a final concentration of 1 mM and the cells were allowed to grow for another 1-4 hours before being harvested by centrifugation (13,689 x g for 20 minutes at 4°C). The media was discarded and the cell pellet stored at -20°C. Upon induction with IPTG, expression of rpilin protein increased significantly and reached maximal levels at three to four hours post induction.

Samples of the induced cultures were analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE). The recombinant pilin was visualized using Coomassie blue staining and its identity confirmed by Western blot with a monoclonal antibody specific for gonococcal pili (clone #A33020023, Biospecific, Emeryville, CA).

Example 3

Construction of Gonococcal Recombinant *pilE* Plasmid Containing Kanamycin Resistance Marker

A plasmid was constructed where the Amp^R marker was replaced with a Kan^R marker. Except as noted below, the procedures of Example 2 were used. A PCR reaction was performed on pTrcHisA plasmid DNA

- 31 -

using TrcFXba primer, 5' GGC TCT AGA CTG TCA GAC CAA
GTT TAC TC 3' (SEQ ID NO:7), and TrcRXba primer, 5' GGC
TCT AGA TTG AAG CAT TTA TCA GGG 3' (SEQ ID NO:8). The
underlined sequences code for an XbaI restriction site.
5 The approximate 3.5 kb PCR product contained the
pTrcHisA DNA minus the ampicillin coding region.
Another PCR reaction was performed on pACYC177 plasmid
DNA (New England Biolabs, Beverly, MA) using KanFXba
primer, 5' GGC TCT AGA TAA ACA GTA ATA CAA GGG G 3'
10 (SEQ ID NO:9), and KanRXba primer, 5' GGC TCT AGA TTA
GAA AAA CTC ATC GAG C 3' (SEQ ID NO:10). Again, the
underlined sequences code for an XbaI restriction site.
The approximate 860 bp PCR DNA product contains the
kanamycin resistance gene. Both PCR products were
15 purified from an agarose gel, the DNAs were digested
with the XbaI restriction enzyme, extracted and ligated
together. An aliquot of the ligation reaction was
transformed into *E. coli* TOP10F' and an aliquot of the
transformation mix plated on SOB plates containing 30
20 $\mu\text{g/mL}$ of kanamycin.

A total of 48 Kan^R colonies were streaked in
duplicate onto SOB plates containing either ampicillin
or kanamycin. As anticipated, all Kan^R colonies were
ampicillin sensitive. Since the cloning design was
25 symmetrical, both orientations of the kanamycin insert
were isolated. The kanamycin insert in the same
clockwise orientation as the original ampicillin gene
was selected for future studies and called pZ564. The
DNA region containing the lacIq gene, trc promoter and
30 the multiple cloning site in pZ564 was then replaced
with the similar region from the pPX2000 plasmid (which
also contained *pilE*) in the following manner: Both
pZ564 and pPX2000 were digested with *SphI* and *XmnI*
restriction enzymes. The approximate 2.2 kb DNA
35 fragment from pPX2000 and the approximate 2.6 kb DNA

- 32 -

fragment from pZ564 were gel purified, ligated together and transformed into *E. coli* TOP10F'. The resulting correct plasmid was called pPX2002.

5 A similar time course of induction and level of recombinant pilin protein expression was seen when the selection antibiotic was changed to kanamycin from ampicillin.

Example 4

10 Cloning and Expression of Meningococcal

Class I pilE in *E. coli*

15 Because of the highly homologous nature of the DNA and amino acid sequences of gonococcal and meningococcal class I pilins (7), the ability of gonococcal rpilin antisera to bind to pili expressed on meningococcal cells was assessed using the whole cell ELISA. This antisera exhibited a titer of 151,100 for binding to *N. meningitidis* pilated cells from strain H355.

20 This binding appeared to be directed against the pilin protein, since a Western blot of the whole cell lysate from this strain showed that only a single band co-migrating with pilin bound the antisera (data not shown). A number of other meningococcal strains exhibited lower titers in the whole cell ELISA, but the presence of pili was not confirmed by transmission electron microscopy. Based on these data, it was decided to clone and recombinantly express the class I pilin from *N. meningitidis*. Initially, the same strategy was followed as with the *pilE* from *N. gonorrhoeae*. Except as noted below, the procedures of Example 2 were used.

30 The class I *pilE* was amplified from the genomic DNA of *N. meningitidis* strain H44/76 using the

35

- 33 -

following primers: 5' CCC CGC GCC ATG GAC ACC CTT CAA
AAA GGT TTT ACC 3' (NMFPILE) (SEQ ID NO:11), and 5' GGG
CCT GGA TCC GAG TGG CCG TGG AAA ATC ACT TAC CGC 3'
(NMRPILE) (SEQ ID NO:12). As anticipated, a PCR
5 product of approximately 600 bp DNA was obtained. An
aliquot of the PCR reaction product was digested with
*Bam*HI and *Nco*I restriction enzymes for insertion into
pTrcHisA. The digested DNAs were electrophoresed on an
agarose gel and the DNA fragments gel purified. The
10 DNA fragments were then ligated together and
transformed into *E. coli* TOP10F'. Miniplasmid prep
analysis of ampicillin resistant clones was performed
using *Bam*HI and *Nco*I restriction enzymes. Clones
expressing the correct restriction digest pattern were
15 called RZ1142 and the plasmid was called pPX2003.

Following induction, the presence of a
Coomassie blue stained polypeptide with a molecular
weight of approximately 15,000 daltons was observed
when a whole cell lysate was analyzed by SDS-PAGE.
20 Analysis of whole cell lysates from four of these
clones by SDS-PAGE and Western blot demonstrated the
presence of a protein of appropriate mobility and
reactivity with polyclonal antisera against the intact
pili from *N. gonorrhoeae* strain LB2. The purified
25 class I *rpilin* was 167 amino acids in length. However,
the level of expression of this recombinant *pilin* was
significantly lower than that obtained with either
pPX2000 or pPX2002 grown under the same conditions. An
analysis of the DNA sequence in the recombinant class I
30 *pile* showed that there were a number of inverted
repeats which might explain the low level of expression
of this protein in *E. coli*.

- 34 -

Example 5Construction and Expression of a Gonococcal and Meningococcal Class I Chimeric *pile* in *E. coli*

5 In order to increase the expression of the meningococcal pilin protein, the DNA encoding the first 60 amino acids in pPX2003 (the meningococcal class I *pile* construct described in Example 4) was replaced with the equivalent region from pPX2002 (the gonococcal *pile* construct described in Example 3, including the seven amino acid signal peptide) (SEQ ID NO:4). Except as noted below, the procedures of Example 2 were followed.

15 The conserved 5' terminal region of the meningococcal *pile* gene was replaced by the same region from *N. gonorrhoeae* strain Pgh3-1 in the following manner. A *Bsm*BI site was introduced into the meningococcal *pile* gene as follows: DNA was PCR amplified from pPX2003 using the following primers: 5' CCG GCG CGT CTC TCA CGG CGA ATG GCC CGG C 3' (CL-1ESPF) (SEQ ID NO:13) and 5' GGG CCT GGA TCC GAG TGG CCG TGG AAA ATC ACT TAC CGC 3' (NMRPILE) (SEQ ID NO:14) and *Taq* DNA polymerase. The expected PCR DNA product was cloned directly into pCR2.1 (Invitrogen) and transformed into TOP10F' cells and the resulting plasmid was designated pZ578. A *Bsm*BI site was then introduced into the gonococcal *pile* by the following method. Using the primers 5' GCA TAA TTC GTG TCG CTC AAG GCG C 3' (TRCUPFW) (SEQ ID NO:15) and 5' GCC GCG CGT CTC CCG TGA TTC AGG TAA TAC TCG G 3' (PILEESPR) (SEQ ID NO:16) and *Pfu* DNA polymerase, the 5' end of the *pile* gene from pPX2000 was PCR amplified. The resulting gonococcal PCR product and pZ578 were then digested with *Bsm*BI and ligated together. The ligated DNAs were

- 35 -

then PCR amplified using 5' GCA TAA TTC GTG TCG CTC AAG GCG C 3' (TRCUPFW) (SEQ ID NO:17) and 5' GGG CCT GGA TCC GAG TGG CCG TGG AAA ATC ACT TAC CGC 3' (NMRPILE) (SEQ ID NO:18) primers.

5 The DNA PCR product was of the predicted size (approximately 850 bp) and was digested with *Nco*I and *Bam*HI to yield an approximately 600 bp fragment. This fragment was gel isolated and cloned directly into *Nco*I- and *Bam*HI-cut pPX2000 vector, replacing the
10 gonococcal *pile*E gene. The resulting plasmid, which was ampicillin resistant, was labeled pPX2004 and used to transform TOP10F'. Analysis of this transformant demonstrated the presence of the desired chimeric *pile*E DNA. Following induction with IPTG, there was a
15 significant increase in the amount of the meningococcal chimeric class I rpilin construct expressed compared to the amount of meningococcal rpilin expressed from pPX2003. Using the extraction with 1% octyl- β -D-glucopyranoside (OG) and purification protocol (TMAE
20 Fractogel™ column in 10 mM Tris™, pH 8.5 with 0.1% (w/v) Zwittergent™ 3-14) described in Example 7 for the recombinant gonococcal pilin, highly purified meningococcal chimeric class I rpilin protein was obtained (yield approximately 5 mg/gram cell wet
25 weight). This material was greater than 90% pure when analyzed by SDS-PAGE and laser densitometry. SDS-PAGE demonstrated the presence of a major band of approximately 15,000 daltons in size. The meningococcal chimeric class I rpilin protein was also
30 167 amino acids in length, and includes the signal sequence of seven amino acids as demonstrated by sequencing of the amino-terminal 36 residues of the purified protein.

- 36 -

Example 6Construction and Expression of a Gonococcal and Meningococcal Class II Chimeric *pile* in *E. coli*

5 The initial cloning of the meningococcal
class II *pile* involved isolation of chromosomal DNA
from piliated *N. meningitidis* strain FAM18 cells and
amplifying the classII *pile* DNA in a PCR reaction. The
class II *pile* gene was amplified using the following
10 primers which recognized the 3' and 5' ends of the
complete pilin protein (including the leader sequence):
5' GCG GCC GCC ATG GAA GCA ATC CAA AAA GGT TTC ACC C 3'
(PILE2FWD) (SEQ ID NO:19) and 5' GCG GCC GGA TCC GGT
CAT TGT CCT TAT TTG GTG CGG C 3' (PILE2REV) (SEQ ID
15 NO:23). In a similar strategy as in Example 2, the
resulting PCR product contained an *Nco*I site at the
beginning of the *pile* coding region and a *Bam*HI site at
the end. The *Nco*I site was introduced into the gene
because of cloning considerations. This resulted in a
20 change of the second amino acid in the signal sequence
from lysine (AAA) to glutamic acid (GAA). As stated
previously, this change was not expected to have any
effect on antigenicity or immunogenicity. The PCR
product was cloned into a pCR2.1 cloning vector
25 (Invitrogen), ligated, and transformed into *E. coli*
TOP10F'. Colonies were selected on 100 µg/mL
ampicillin-containing plates or 50 µg/ml kanamycin
plates. The plasmid DNA was isolated from overnight
cultures of these transformants and analyzed by
30 restriction digests using the enzyme *Eco*RI.

Clone #8, designated pPX8001, was used as the
source of the *pile* gene. Plasmid DNAs from pPX8001 and
pTrcHisC (Invitrogen) were each digested with *Nco*I and
*Bam*HI restriction enzymes, and the resulting DNA
35 fragments were gel isolated, ligated and transformed

- 37 -

into *E. coli* TOP10F'. Following selection of
ampicillin resistant colonies, the plasmid DNA of the
new transformants were isolated, and a DNA restriction
analysis performed using *Bam*HI and *Nco*I restriction
5 enzymes. Two clones with the correct restriction
pattern were submitted for DNA sequence analysis. Both
clones had the correct DNA sequence, designated as
pPX8002.

To test for expression of the recombinant
10 class II pilin, 10 mL cultures containing these clones,
pPX8002, were grown in 50 mL tubes in SOB containing
100 μ g/mL ampicillin and 12 μ g/mL tetracycline, to an
 $A_{600} = 1.0$. Expression of the recombinant protein was
induced by adding IPTG to final concentration of 1 mM
15 and the culture was continued for three hours. When a
whole cell lysate of the induced cells was separated by
SDS-PAGE and stained with Coomassie blue, no new
(induced) band was detected. This suggested that the
FAM18 *pile* gene product was expressed at levels lower
20 than those discernable with Coomassie blue. When the
FAM18 *pile* was cloned into the pET17b plasmid and
transformed into *E. coli* BL21(DE3)pLysS with or without
the *pile* signal sequence, no significant expression of
recombinant protein was detected. Similar results were
25 obtained when the class II *pile* gene from two other
strains of *N. meningitidis* (NmB, 2996) were cloned into
the same pTrcHis plasmid and TOP10F' expression system.

Specifically, the strains NMB and 2996 were
also determined to be expressing the class II pilin,
30 based on PCR and sequencing data. The *pile* gene was
amplified from several *N. meningitidis* strains using a
class I set of primers (NMFPILE and NMRPILE) and a
class II set of primers (PILE2FWD and PILE2REV) in
separate reactions with either chromosomal DNA or cells
35 as the template. PCR products were cloned into

- 38 -

pTrcHisC and sequenced, or were sequenced directly. Alignments of sequences were carried out; sequences similar to those from the H44/76 strain were classified as class I, while sequences similar to those from the
5 FAM18 strain were classified as class II. Sequences were not obtained for all the strains amplified. A preliminary classification was also made based on PCR data. Class I strains were those which gave a correct
10 size PCR product with class I primers but not with class II primers, while class II strains were those which gave a correct size PCR product with class II primers but not with class I primers.

Based on the experience with the meningococcal class I pilin, the region encoding the
15 first 60 amino acids (the conserved amino-terminal region) of the class II *pile* were replaced with the corresponding region from *N. gonorrhoeae* strain Pgh3-1. Expression of the resulting chimeric *pile* was investigated in a number of *E. coli* expression strains
20 using a variety of promoters. The strains studied included: PR13 (Rnase deficient), BL21 (protease deficient), KS474 (deficient in periplasmic protease), AD494 (Novagen, which allows disulfide bond formation in cytoplasm) and three strains of TOPP (Stratagene,
25 non-K12 strains useful for hard to express proteins). In all cases, no recombinant protein was detected in Coomassie blue- stained SDS-PAGE. An alternative expression plasmid pET17b (which includes a T7 promoter) was investigated with similar results.

30 It should be noted that the native class II *pile* gene sequence in pPX8002 ends at base 447. The DNA sequence found downstream (3') from the native meningococcal classII *pile* termination site, nucleotides 447 to 519, contains an inverted repeat
35 which might form a stem and loop structure. Because

- 39 -

stem and loop structures can be effective terminators of transcription, it was postulated that the omission of this additional 3' sequence (74 bases) in pPX8002 might affect the transcription of the chimeric class II *pilE* message in *E. coli*. Therefore, all subsequent cloning restored this downstream 3' end sequence.

A systematic replacement of various portions of the class II *pilE* gene from the *N. meningitidis* strain with the corresponding regions of the *pilE* gene from *N. gonorrhoeae* strain Pgh3-1 was undertaken in order to identify regions that inhibited expression. Replacement regions started at the 5' or 3' ends and were made progressively larger. Double replacements of 5' and 3' ends were also constructed until an internal region of only 84 nucleotides from the native *pilE* class II remained. This region was also replaced, resulting in the reconstruction of the rGC and, as expected, this clone expressed rpilin at similar Coomassie blue stained levels as pPX2000. The following regions (listed by nucleotide numbers) of the FAM18 *pilE* gene were replaced with the corresponding regions from Pgh3-1 (listed in parentheses): single region replacements were 1-108 (1-108), 1-181 (1-181), 1-294 (1-282), 439-499 (478-553), 379-519 (367-553), 295-519 (283-553), 295-378 (283-366); double region replacements were 1-294 (1-282) & 379-519 (367-553), 1-181 (1-181) & 439-499 (478-553), 1-181 (1-181) & 379-519 (367-553), 1-294 (1-282) & 439-499 (478-553).

When these constructs were expressed in *E. coli* TOP10F' using the pTrcHis expression system, two constructs produced recombinant protein at levels detectable by Coomassie blue: the first containing the replacement of nucleotides 379-519 (which comprises the disulfide loop and 3' extension); and the second containing the replacement of both nucleotides 1-181

- 40 -

(which comprises the conserved 5' region) & 379-519 (which comprises the disulfide loop and 3' extension). Because replacement of the 5' region alone did not lead to expression of recombinant protein and because the first construct retained most of the native meningococcal pilin sequence, this construct (nucleotides 379-519) was selected for further investigation. While the amino acid sequence of the meningococcal and gonococcal proteins are significantly different in this region, it is well documented (17,18) that the disulfide loop undergoes significant antigenic variation. Therefore, any immune response directed against this region (e.g., the disulfide loop) would exhibit minimal cross-reactivity among meningococcal strains. Lastly, because the gonococcal insert is nearly twice the size of the meningococcal disulfide loop (39 residues versus 18 residues), the resulting chimeric protein migrates on an SDS-PAGE gel with an apparent molecular weight of approximately 19,000 daltons.

The construction of this chimeric gene was carried out in the following manner. The 5' fragment was obtained by amplifying pPX8002 (FAM18 class II *pile*) with the following primers: 5' GCG GCC GCC ATG GAA GCA ATC CAA AAA GGT TTC ACC C 3' (PILE2FWD) (SEQ ID NO:19) and 5' GCC GCG CGT CTC CGA ACC GGA GTT TTG TTT GCC 3' (REV-CYS) (SEQ ID NO:20). The gonococcal disulfide loop (i.e., the 3' end of the gonococcal gene) was amplified from pPX2000 using primers 5' CCG GGC CGT CTC GGT TCG GTA AAA TGG TTC TGC 3' (FWD-CYS) (SEQ ID NO:21) and 5' GGG CCT GGA TCC GTG GGA AAT CAC TTA CCG 3' (PILEREV) (SEQ ID NO:22). The resulting PCR products were each purified, digested separately with restriction enzyme *BsmBI*, then ligated to form the full length chimeric *pile*, which was amplified using primers

- 41 -

PILE2FWD and PILEREV. This PCR product was digested with restriction enzymes *NcoI* and *BamHI*, ligated into a similarly restricted pTrcHisC vector and transformed into TOP10F' competent cells.

5 Transformants were cultured and analyzed using the restriction enzymes *NcoI* and *BamHI*. Four clones with the right sized insert were analyzed with restriction enzyme *StuI*. Of these, three provided the correct restriction map. Two of the three clones with
10 the correct restriction pattern were sequenced. Clone #5 had the correct DNA sequence and was designated as pPX8017. This clone contains the nucleotide sequence set forth in SEQ ID NO:3, in which nucleotides 1-378 are from *N. meningitidis* and nucleotides 379-510 are
15 from *N. gonorrhoeae*.

Expression was checked with 10mL cultures in 50mL tubes. Cells were grown in SOB supplemented with 100 µg/ml ampicillin and 12 µg/ml tetracycline until A_{600} approximately 1.0. A culture was induced by the
20 addition of IPTG to a final concentration of 1 mM. Growth was allowed to continue for 3-4 hours, at which point the cells were collected by centrifugation (13,689 x g for 20 minutes at 4°C) and stored at -20°C. For the fermentor, an overnight culture from a plate or
25 frozen stock was used to inoculate a flask containing 500 mL media which was again grown overnight. This liquid culture was then used to inoculate a Biostat B Fermentor (Braun Biotech, Allentown, PA) containing 8.9 L of media. Enhanced growth of the bacteria in the
30 fermentor was obtained when HySoy™-containing media was supplemented with dextrose at a final concentration of 1% (w/v). When the culture reached $A_{600} = 4.0-6.0$, IPTG was added to a final concentration of 1 mM and the cells were allowed to grow for another 2-4 hours before
35 being harvested by centrifugation (13,689 x g for 20

- 42 -

minutes at 4°C). The media was discarded and the cell pellet stored at -20°C. Upon induction with IPTG, expression of chimeric class II rpilin protein increased significantly.

5 Samples of the induced cultures were analyzed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE). The recombinant meningococcal chimeric class II pilin was visualized using Coomassie blue staining (apparent molecular
10 weight of approximately 19,000 daltons) and its identity confirmed by Western blot with a polyclonal antisera directed against a gonococcal peptide (Glu Ala Ile Leu Leu Ala Glu Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Lys) (SEQ ID NO:24), which is
15 located in the conserved region of the amino terminus of the class II pilin protein. The meningococcal chimeric class II rpilin was 170 amino acids in length (including the signal) (SEQ ID NO:4), in which amino acids 1-126 are from *N. meningitidis* and amino acids
20 127-170 are from *N. gonorrhoeae*.

Example 7

Isolation and Purification of Recombinant Gonococcal Pilin from *E. coli*

25 The following procedure was used to purify the recombinant gonococcal pilin obtained in Examples 2 and 3 above. This procedure is also used to purify the meningococcal recombinant pilin obtained in Example 4,
30 and was used initially to purify the meningococcal chimeric class I rpilin protein obtained in Example 5, above. Subsequently, the isolation procedure for the meningococcal chimeric class I rpilin protein was modified as described in Example 8 below.

- 43 -

Sub-cellular fractionation of the *E. coli* expressing rpilin demonstrated that the protein was associated with the cellular membranes, most likely the inner membrane, based on the ability of 1% (v/v) Triton™ X-100 to solubilize this protein. When an attempt was made to remove contaminating *E. coli* proteins in the presence of 0.05-0.1% (v/v) Triton™ X-100, it was discovered that, below pH 9.5, the rpilin did not bind consistently to an ion exchange column. Therefore, the ability of a number of detergents to selectively solubilize the rpilin protein from *E. coli* membrane preparations was examined.

The cell pellet (approx. 5 g wet weight) from 1 L of culture was thawed by adding 30 mL of 10 mM Hepes (pH 7.2) (Research Organics, Cleveland, OH), 1 mM EDTA and the cells broken using a Microfluidizer cell homogenizer (Microfluidics International Corp., Newton, MA). The lysate was clarified by centrifugation (12,000 x g for 10 minutes) and the membranes pelleted (288,652 x g for one hour). The membranes were resuspended in 33 mL of 10 mM Hepes (pH 7.4), 1 mM MgCl₂ and extracted with one of the following detergents: (a) Triton™ X-100 (TX100) (Calbiochem-Novabiochem International, San Diego, CA), (b) reduced Triton™ X-100 (Calbiochem), (c) octyl-β-D-glucopyranoside (OG) (Calbiochem), (d) Zwittergent™ 3-8 (Z3-8) (Calbiochem), (e) Zwittergent™ 3-10 (Z3-10) (Calbiochem), (f) Zwittergent™ 3-12 (Z3-12) (Calbiochem), (g) Zwittergent™ 3-14 (Z3-14) (Calbiochem), (h) Empigen BB™ (Calbiochem) or (i) Tween™ 80 (ICN, Cleveland, OH) for one hour at room temperature.

Empigen™ BB (1% v/v), Zwittergent™ 3-10 (1% w/v), reduced Triton™ X-100 (1% v/v), octyl glucoside (1% w/v) with Zwittergent™ 3-10 (1% w/v) or 3-14 (0.1%

- 44 -

w/v) each selectively extracted the recombinant pilin protein with minimal contamination with the *E. coli* proteins. Zwittergent™ 3-12, even at 0.1% (w/v), solubilized both the recombinant protein and a significant number of *E. coli* proteins. Tween™ 80 did not extract the recombinant protein at any tested concentration (0.1-1% v/v).

The solubilized proteins were separated from insoluble membrane material by centrifugation (288,652 x g for one hour). The supernatant (containing rpilin) was dialyzed overnight at 4°C against 10 mM Tris™ (pH 8.5) containing one of the following non-ionic detergents: (a) 0.1% (w/v) Zwittergent™ 3-14, (b) 1% (w/v) Zwittergent™ 3-10 or (c) 1% (w/v) OG. The dialyzed material was fractionated on a Fractogel™ EMD TMAE-650(S) (EM Separations Technology, Wakefield, RI) column equilibrated in 10 mM Tris™ (pH 8.5) and the respective detergent. The bound protein was eluted with a linear gradient of 0 to 0.2 M NaCl in 10 mM Tris™ (pH 8.5) containing the appropriate detergent. Fractions containing rpilin were pooled, analyzed for purity and protein content. Occasionally, to increase the purity of the rpilin, the pooled material was dialyzed against the starting buffer and fractionated a second time on the TMAE column.

The rpilin, which was selectively eluted from the column, was highly purified, as judged by laser densitometric analysis of a Coomassie blue stained SDS-PAGE (>90% homogeneous). Similar results were obtained when the extraction and column chromatography were done with 1% (w/v) Zwittergent™ 3-10, 1% (w/v) OG or 0.1% (w/v) Zwittergent™ 3-14. The yield of rpilin, which was a significant proportion of the total *E. coli* protein, was approximately 10 mg/L of culture grown in 1.5 L shake flasks with SOB media. When the

- 45 -

recombinant *E. coli* (containing pPX2002) were grown in a fermentor using HySoy™ based media, the yield of purified rpilin increased to approximately 30 mg/L of culture, which corresponds to seven mg rpilin per gram of cell mass. When 1% dextrose was included in the fermentor, the overall yield of rpilin increased to approximately 100 mg/L.

The purified rpilin was dialyzed against 10 mM sodium phosphate, 140 mM NaCl (pH 7) (PBS) containing 0.05% (w/v) Z3-14, sterile filtered and stored at 4°C or frozen at -20°C.

Example 8

Isolation and Purification of Meningococcal Chimeric Class I rpilin from *E. coli*

Large scale cultures of *E. coli* cells containing pPX2004 were grown in a Biostat B Fermentor as described in Example 2. Bacterial cells (approximately 88 grams wet weight of *E. coli* pPX2004) were resuspended in 440 mL of 10 mM Hepes, 1 mM EDTA (pH 7.5) and disrupted using a Microfluidizer Model 110Y (Microfluidics Corp., Newton, MA). The disrupted cells were clarified by centrifugation at 6,084 x g for 20 minutes at 10°C. The supernatant was collected and the membrane fraction isolated by centrifugation at 205,471 x g for 1 hour at 10°C. The pellet was resuspended by homogenization in 220 mL of 10mM Hepes, 1 mM MgCl₂, 1% (w/v) octyl-β-D-glucopyranoside (pH 7.5) and stirred for 90 minutes at room temperature. The suspension was centrifuged at 205,471 x g for one hour at 10°C. Following centrifugation, the supernatant, which contained the solubilized chimeric class I rpilin, was filtered through a 0.22μ Nalgene vacuum filter and stored at 4°C. The pH of the octylglucoside

- 46 -

extract was adjusted to pH 8.5 with concentrated NaOH and subsequently loaded onto a 200 mL TMAE Fractogel™ column (EM Separations Technology, Gibbstown, NJ) equilibrated with 25 mM Tris™, 0.1% (w/v) Zwittergent™ 3-14 (pH 8.5). Unbound protein was washed through the column with an additional 400 mL of the equilibration buffer. The rpilin was eluted using a linear NaCl gradient (0-0.2 M NaCl) in 25 mM Tris™, 0.1% (w/v) Zwittergent™ 3-14 (pH 8.5) over 10 column volumes at a flow rate of 10.0 mL/minute. Fractions containing the chimeric class I rpilin were pooled and diluted 1:1 with dH₂O and loaded onto a 100 mL 40 μm ceramic hydroxyapatite column (Bio-Rad, Hercules, CA) equilibrated with 10 mM NaPO₄, 0.1% (w/v) Zwittergent™ 3-14 (pH 6). Unbound protein was washed through the column with an additional 200 mL of equilibration buffer. The chimeric class I rpilin was eluted using a linear NaPO₄ gradient (10-150 mM NaPO₄) containing 0.1% (w/v) Zwittergent™ 3-14 over 10 column volumes at a flow rate of 5.0 mL/minute. Fractions were screened by SDS-PAGE analysis and those containing the chimeric class I rpilin were pooled. The purified material was at least 95% pure, as determined by laser densitometry of Coomassie blue-stained gels. The yield of purified chimeric class I rpilin was approximately 35 mg/g wet weight cells.

Example 9

Isolation and Purification of Meningococcal Chimeric Class II rpilin from *E. coli*

All steps were performed at room temperature unless specified. Frozen *E. coli* cells were resuspended in 10 ml of 10 mM Hepes (pH 7.2), 1 mM EDTA

- 47 -

per gram of cells and homogenized using a Microfluidizer cell homogenizer to disrupt the cells. The cell lysate was clarified by centrifugation at 13,689 x g for 30 minutes. The resulting supernatant was then centrifuged at 388,024 x g for 30 minutes at 4°C. The supernatant was discarded and the pellet containing the membranes was frozen at -20°C overnight. The membrane pellet was resuspended in 9 mL/tube of 10 mM Hepes (pH 7.2), 1 mM MgCl₂ and extracted with 1% (w/v) Zwittergent™ 3-16 (Calbiochem) for one hour. The suspension was centrifuged at 388,024 x g for 30 minutes and the resulting pellet was extracted again with Zwittergent™ 3-16 as described above. Following centrifugation (388,024 x g for 30 minutes), the pellet was resuspended into 9 mL of 50 mM Tris™ (pH 8.0), 5 mM EDTA and extracted with 1% (w/v) N-laurylsarcosyl (Sigma) with gentle agitation overnight at room temperature. This resulted in the solubilization of the meningococcal chimeric class II rpilin. The insoluble material was removed by centrifugation (388,024 x g for 30 minutes) and discarded. Zwittergent™ 3-14 was added to the supernatant, which contained the meningococcal chimeric class II rpilin, to a final concentration of 1% (w/v) and the material was dialyzed overnight against 50 mM Tris™ (pH 8.0), 10 mM EDTA, 1% Zwittergent™ 3-14. An aliquot (1 mL, 1.3mg protein) of the dialyzed material was then passed over a Mono-Q™ (Pharmacia, Piscataway, NJ) column (5x10 mm) which was equilibrated in 50 mM Tris™ (pH 8.0), 10 mM EDTA, 1% (w/v) Zwittergent™ 3-14 at a flow rate of 0.5 mL/minute. The unbound material containing the chimeric class II rpilin was pooled and dialyzed overnight against 10 mM NaPO₄ (pH 6.8), 1% (w/v) Zwittergent™ 3-14. This material was approximately

- 48 -

80% pure and was used in the studies described in Examples 26 and 27 below. Further purification of this material was obtained by passing it over a 1 mL hydroxyapatite column (Bio-Rad) which was equilibrated
5 in 10 mM NaPO₄ (pH 6.8), 1% (w/v) Zwittergent™ 3-14. The purified meningococcal chimeric class II protein was eluted with a linear gradient of 0-0.5M NaPO₄ containing 1% (w/v) Zwittergent™ 3-14. Fractions were screened for chimeric class II rpilin by SDS-PAGE,
10 using gels which were stained with either Coomassie blue or silver. Both analyses demonstrated the presence of a single polypeptide band which had a molecular weight of approximately 19,000 daltons. This material was shown to be greater than 95% pure by laser
15 densitometric analysis of the polyacrylamide gels.

Example 10

Analytical Methods for Gonococcal rpilin

20 Protein content was determined by the bicinchoninic acid protein assay (Pierce, Rockford, IL) using BSA as the standard. The purity of protein preparations was determined by Coomassie brilliant blue stained polyacrylamide gel electrophoresis in the
25 presence of SDS (SDS-PAGE) and analyzed by laser densitometry with a Personal Densitometer SI (Molecular Devices). The identity of pilin in the preparations was confirmed by Western blotting using the monoclonal antibody described in Example 2, which is raised
30 against purified pili from *N. gonorrhoeae* strain P9 (Biospecific). The N-terminal sequences of the pilin proteins were determined using an Applied Biosystems 477A Protein Sequencer. Two sequences were often
35 detected when the purified rpilin was submitted for N-terminal sequencing. The major sequence represented

- 49 -

the complete pilin protein, including the seven amino acid leader sequence. The minor sequence, comprising 10-20% of the sample, was rpilin protein in which the leader sequence was missing and the sequence started at phenylalanine, the N-terminal residue of the mature gonococcal pilin protein. For both rpilin protein forms, sequencing of the amino-terminal residues gave results which agreed with the sequence deduced from the DNA sequence.

The mass of recombinant pilin was determined by matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry using a Finnigan MAT Lasermat™ 2000 (San Jose, CA). The instrument was calibrated with horse myoglobin to within 0.01% of its expected mass of 16,951.5 daltons. Recombinant pilin was mixed with an equal volume of a cyano-4-hydroxycinnamic acid matrix (10 mg/mL in 70:30 acetonitrile : 0.1% (v/v) trifluoroacetic acid/water). An aliquot (1 μ L) of this mixture was deposited on a sample stage, allowed to air dry, and subjected to MALDI-TOF mass spectrometry analysis. Data from 15 runs (each run representing a sum of 10 shots) were averaged to determine the mass of rpilin. The molecular weight of the rpilin (with signal) was determined to 18,001 daltons, which compares well to the predicted mass of 17,981 daltons based on the amino acid content. A minor peak with a mass of 17,232 daltons (average) was detected in each lot. The difference in molecular weights of the two forms of the recombinant pilin (769 daltons) is ascribed to the loss of the first six amino acids of the leader sequence (Met Asp Thr Leu Gln Lys) (SEQ ID NO:2, amino acids 1-6) which has a mass of 774 daltons.

A very different apparent molecular weight of the rpilin was obtained by size exclusion column

- 50 -

chromatography using an analytical Superose™ 12 column (Pharmacia, Piscataway, NJ) equilibrated in PBS containing 0.05% (w/v) Zwittergent™ 3-14. Under these conditions, the protein eluted at a position
5 corresponding to a molecular weight of 68,899. This suggested that the recombinant protein aggregated. However, the elution of a protein from a size exclusion column can be greatly influenced by the shape of the protein. Results from velocity sedimentation
10 centrifugation experiments demonstrated that the recombinant pilin had a molecular weight in solution of approximately 45,000 daltons. In an attempt to remove the detergent (Zwittergent™ 3-14), the recombinant protein was dialyzed extensively against PBS alone.
15 The dialyzed recombinant protein appeared soluble and was not pelleted by high speed centrifugation (122,000 x g for one hour). No attempt was made to verify the complete removal of the detergent from the recombinant protein. Analysis of this material by gel filtration
20 in PBS indicated that the protein had an apparent molecular weight of 452,349 daltons. This suggested that it had undergone further aggregation. The number of subunits in either aggregate has not been determined.

25 The value of 452,349 must be considered an estimate, because the protein may still be in a micelle, as it is unknown if the detergent was completely removed from the sample. Given the fact that rpilin is diluted approximately 15-30 fold when
30 formulated as a vaccine, it appears likely that the rpilin in the vaccine will have an apparent molecular weight of approximately 450 kD.

35

- 51 -

Example 11Preparation of Immune Sera from rpilin

5 Immunogenicity studies were performed using guinea pigs (female, 200 g) immunized subcutaneously (s.c.) with 20 μg of purified gonococcal rpilin protein mixed with an adjuvant. The adjuvants studied were: (a) Stimulon[™] QS-21 (25 $\mu\text{g}/\text{dose}$) in PBS (pH 6); (b) 10 aluminum phosphate (Lederle Laboratories, Pearl River, NY, 100 $\mu\text{g}/\text{dose}$) in PBS (pH 7); or (c) PBS (pH 7) only. Initially, the animals were immunized on weeks 0, 4 and 8 and sera were obtained on weeks 0, 4, 6 and 10. Analysis of the time course of the immune response demonstrated that giving a third vaccination at week 8 15 did not boost the immune response and, therefore, later studies with the recombinant pilin were terminated at the week 6 bleed.

In order to investigate the ability of adjuvants to modulate the immune response of gonococcal 20 rpilin, mice (female, 8 weeks old, 5 or 10 animals per group) were immunized subcutaneously with 1-10 μg of purified protein on weeks 0, 4 and 6 and sera were obtained on weeks 0, 4, 6 and 8. Vaginal lavages were done at week 8 by instilling RPMI 1640 (75 μL) into the 25 vagina and aspirating 3-4 times. The lavage fluids from each group were pooled together and 50 μL of fetal bovine serum was added to each pool.

For the meningococcal chimeric class I rpilin protein, the mice received immunizations on week 0 and 30 4 only and sera was obtained on weeks 0, 4 and 6. For all rpilin parenteral immunogenicity studies in mice, the following adjuvants were studied: (a) Stimulon[™] QS-21 (25 $\mu\text{g}/\text{dose}$) in PBS (pH 6); (b) aluminum phosphate (100 $\mu\text{g}/\text{dose}$) in PBS (pH 7); (c) MPL[™] (50 35 $\mu\text{g}/\text{dose}$) in PBS (pH 7); (d) aluminum phosphate (100

- 52 -

$\mu\text{g}/\text{dose}$) and MPL™ (50 $\mu\text{g}/\text{dose}$) in PBS (pH 7); or PBS (pH 7) only.

For the meningococcal chimeric class II rpilin protein, the guinea pigs received immunizations of 20 μg protein adjuvanted with Stimulon™ QS-21 (25 $\mu\text{g}/\text{dose}$) in PBS (pH 6) on week 0 and 4 only and sera was obtained on weeks 0, 4 and 6.

The ability of the recombinantly expressed pilins (either gonococcal or meningococcal chimeric class I) to induce a mucosal immune response was assessed by immunizing mice intranasally with (a) 1 or 10 μg of gonococcal rpilin in 2.5 μL of saline with or without 1 μg of native cholera toxin, or (b) 5 μg of chimeric class I rpilin diluted in 10 μL of PBS (pH 7), with or without 1 μg of mutant CT-CRM, E29H cholera toxin. The immunizations were given on weeks 0, 2 and 3.

Example 12

Western Blot Analysis of the Immune Response Against Gonococcal rpilin

The purified gonococcal rpilin was used to immunize guinea pigs following the protocol described in Example 11. The antisera derived from guinea pigs immunized with gonococcal rpilin were analyzed first by Western blots (data not shown). These blots demonstrated that the antisera against gonococcal rpilin recognized a band corresponding to pilin in whole cell lysate from piliated gonococcal cells; there was no staining seen in non-piliated cell lysate from the same gonococcal strain.

Comparative data were obtained from antisera from guinea pigs immunized with the gonococcal pilin oligomer. Pilin oligomer was obtained by dissociation

- 53 -

of intact pili as previously described (4). Briefly, this involved dialysis of intact pili against 37 mM sodium phosphate (pH 12) for 48 hours at 4°C, followed by dialysis against 50 mM Tris™, 145 mM NaCl (pH 8.0).
5 The pilin oligomers were then clarified by centrifugation (100,000 x g for one hour). Following centrifugation, the pilin oligomers remained in the supernatant. In comparison to antisera against gonococcal rpilin, pilin oligomer antisera, while
10 binding to pilin in the piliated cell lysate, also bound to a number of other bands in the lysates from both piliated and non-piliated cells (data not shown). These bands represent contaminants in the pilin oligomer preparation and are presumed to be not
15 associated with pili.

Example 13

Recombinant Gonococcal Pilin ELISA

20 The endpoint titers against purified proteins or bacterial cells were determined by ELISA. In all ELISA procedures, incubations were for one hour at room temperature, unless otherwise specified. Endpoint
25 titers were defined as the extrapolated dilution at which the optical absorbance was 0.10 greater than that of the blank wells (which do not contain primary antibody). For the analysis of guinea pig antisera, purified recombinant pilin was diluted in 0.1 M Tris™
30 (pH 8) to a final concentration of 1 µg/mL. Aliquots (100 µL) were added to the wells of a microtiter plate (Immulon II, Nunc, Naperville IL) and incubated overnight at 4°C. The plates were washed five times
35 with PBS containing 0.05% (v/v) Tween™-20 (PBS-T) using a Skanwash 300 plate washer (Skatron Instruments, Alexandria, VA). The wells were blocked using 200 µL

- 54 -

of 1% (w/v) BSA in PBS-T, washed and aliquots of antisera (diluted in 0.1% (w/v) BSA in PBS-T) were added to the wells. The plate was then washed and the bound primary antibodies were detected using 100 μ L of alkaline phosphatase conjugated to rabbit anti-guinea pig IgG (heavy & light chains) (Zymed Laboratories, South San Francisco, CA) diluted 1:2000 dilution in 0.1% (w/v) BSA in 50 mM Tris™ (pH 8). The plates were washed and the color developed using 100 μ L per well of p-nitrophenol phosphate (Sigma) (2 mg/mL in 0.5 M diethanolamine, 0.25 mM MgCl₂, pH 9.8). After 30 minutes, the reaction was stopped by adding 50 μ L of 3 N NaOH. The absorbance was read in a Thermomax ELISA plate reader (Molecular Devices, Sunnyvale, CA) at 405 nm.

All the animals immunized with rpilin responded very well, as demonstrated by the antigen ELISAs shown in Table 1.

Table 1

Endpoint Titers for the Binding of Pooled Guinea Pig Antisera Against Gonococcal rpilin to Purified Recombinant Gonococcal Pilin Protein*

Prep	Immunogen	Endpoint Titers		
		Week 0	Week 4	Week 6
1	r Pgh3-1 pilin (Prep 1)	≤100	51,345	494,805
2	r Pgh3-1 pilin (Prep 2)	54	30,237	594,298
3	r Pgh3-1 pilin (Prep 3)	≤100	24,830	546,682

* Three different lots of rpilin were used as immunogen. Guinea pigs were immunized (s.c.) on weeks 0

- 55 -

and 4 and bled on weeks 0, 4 and 6. Analyses were done on pooled sera.

Effect of Adjuvants on Immune Response

5 The effect of the following adjuvants upon the immune response against gonococcal rphilin was studied in mice: (a) Stimulon™ QS-21 in PBS (pH 6); (b) aluminum phosphate in PBS (pH 7); (c) MPL™ in PBS (pH 7); (d) aluminum phosphate and MPL™ in PBS (pH 7);
10 or PBS (pH 7) only. For the analysis of the mouse antisera, the antigen ELISA protocol was modified as follows. The microtiter plates (Costar EIA/RIA, Corning Costar, Cambridge, MA) were coated with 100 μL of 1 μg/mL rphilin in PBS overnight at 37°C. The plate
15 was washed five times using PBS containing 0.1% (v/v) Tween™-20 using a Skantron 300 plate washer. The wells were blocked with PBS containing 0.1% (w/v) gelatin and 0.02% (w/v) NaN₃. The primary antibody was diluted in PBS containing 0.1% (w/v) gelatin, 0.05%
20 (v/v) Tween™-20 (PBS-TG) and 0.02% (w/v) NaN₃ and 100 μL aliquots were incubated in the microtiter plate for 2 hours. After washing, the bound primary antibody was detected using biotinylated rabbit anti-mouse IgG (Fc region) (Brookwood Biomedical, Birmingham, AL) diluted
25 1:8000 in PBS-TG and 0.02% (w/v) NaN₃. The plate was washed and the secondary antibody was detected, in turn, using streptavidin conjugated horseradish peroxidase diluted 1:5000 (Zymed Laboratories) in PBS-TG and 0.02% (w/v) NaN₃ (30 minute incubation). The
30 plate was washed and the color was developed using 0.5 mg/mL 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) in 0.1 M citrate (pH 4.2) containing 0.03% (v/v) hydrogen peroxide for 30 minutes and monitored at 405 nm using an SLT 340 ATTC microplate reader (SLT
35 Labinstruments, Research Triangle Park, NC). The data

- 56 -

were plotted using a log-log plot and the endpoint titers were determined as previously described.

5 When the rpilin was adjuvanted with MPL™, a humoral immune response in mice was obtained, which was similar in magnitude to that seen with Stimulon™ QS-21 (Table 2A). Analysis of vaginal washes from the same animals also revealed a demonstrable IgG titer in the vaginal washes of these animals (Table 2B).

Table 2A
Effect of adjuvants on the immune response to gonococcal rpilin*

Humoral:

	Antigen ELISA	Whole Cell ELISA					
		Homologous Strain	Heterologous Strains				
Adjuvant	rpilin	Pgh3-1	LB2	#11	T-1	I756	
AlPO ₄	361,260	249,410	93,444	141,622	42,535	89,615	
MPL™	1,262,735	902,891	499,223	586,642	165,301	321,340	
AlPO ₄ + MPL™	1,159,670	265,269	112,856	160,814	41,368	110,162	
Stimulon™ QS-21	4,915,200	1,053,446	478,338	440,014	111,753	333,341	

Table 2B
Effect of adjuvants on the immune response to gonococcal rpilin*

Vaginal Lavages**:

Adjuvant	rpilin Titers		Whole Cell Titers***	
	IgG	IgA	LB2 P+	LB2 P-
ALPO ₄	1,452	262	68	≤50
MPL™	6,409	26	1,128	0
ALPO ₄ + MPL™	938	12	120	≤50
Stimulon™	2,716	175	311	37
QS-21				

5

* Balb/c mice (5 per group) were immunized with 10 µg of rpilin adjuvanted as described above on week 0, 4 and 6. The animals were bled on weeks 0, 4, 6 and 8. Analyses were done on pooled sera from week 8. Endpoint titers for week 0 were ≤ 5,000.

** Pooled vaginal lavages were obtained on week 8.

*** Whole cell ELISA using dried cells.

P+: piliated cells. P-: non-piliated variants derived from piliated parental cells.

10

Example 14
Gonococcal Whole Cell ELISA

5 The expression by the rpilin of a significant
number of the cross-reactive epitopes found on the
intact, assembled pili was subsequently verified in the
whole cell ELISA, where antisera against purified
rpilin exhibited high titers against numerous
gonococcal strains expressing heterologous pili. The
10 ability of guinea pig antisera to bind to live
gonococcal cells was done using the following protocol.
Microtiter plates (Immunolon II) were incubated
overnight with 100 μ L of 0.01% (w/v) poly-L-lysine
(Sigma) in PBS at 4°C. Overnight agar cultures of
15 bacteria were harvested into PBS with a Dacron swab and
the turbidity of the suspension adjusted to an $A_{600} =$
1.0. The poly-lysine solution was discarded from the
microtiter plate and 100 μ L aliquots of the bacterial
suspension added to the wells. The plates were washed
20 five times with PBS using a hand-held Nunc plate washer
and blocked with 200 μ L of PBS containing 1% (w/v) BSA
(PBS-B). The plates were then washed five times with
PBS and 100 μ L aliquots of antisera diluted in 0.1%
(w/v) BSA in PBS were added to the wells. After
25 washing five times with PBS, the bound antisera was
detected using 100 μ L of the appropriate alkaline
phosphatase conjugates listed above at a 1:2000
dilution in 0.1% (w/v) BSA in PBS. The plates were
washed, the color developed and the absorbance read (at
30 30 minutes development) as described above.

35 When analyzed by the whole cell ELISA, the
guinea pig antisera against rpilin bound to piliated
isolates from diverse geographical locations, but not
to the corresponding non-piliated cells of the same
gonococcal strain (Table 3).

Table 3
 Endpoint Titers for the Binding of Guinea Pig Antisera
 Against rpilin to Live Gonococcal Cells from Diverse Strains*

Strain	Source	Pgh3-1 rpilin (Prep 1)	Pgh3-1 rpilin (Prep 2)	Pgh3-1 rpilin (Prep 3)
Pgh 3-1 P+	Pittsburgh	2,940,971	2,461,272	2,373,641
Pgh 3-1 P-	Pittsburgh	<250	<250	<250
LB2 P+	Unknown	505,439	481,815	825,517
LB2 P-	Unknown	187	34	114
I-756 P+	Ontario,	689,309	713,904	1,026,231
	Canada			
1948 P+	Romania	290,367	259,487	325,640
1635P P+	Panama	2,714,006	≥546,750	≥546,750
22714FB P+	Fort Bragg, NC	397,763	346,895	498,882
T-1 P+	Unknown	189,490	317,370	272,828
M-2 P+	Unknown	124,906	117,734	151,966
3138K P+	Korea	220,730	179,127	584,044

Table 3 (continued)
 Endpoint Titers for the Binding of Guinea Pig Antisera
 Against rpilin to Live Gonococcal Cells from Diverse Strains*

Strain	Source	Pgh3-1 rpilin (Prep 1)	Pgh3-1 rpilin (Prep 2)	Pgh3-1 rpilin (Prep 3)
N-2 P+	Norfolk, VA	350,210	337,232	435,164
J474B P+	Jamaica	238,640	205,247	380,970
Fresh Clinical Isolates				
52407 P+	Tampa, FL	598,124	890,678	778,607
#11 P+	Rochester, NY	214,673	292,358	385,985
FA1090:				
2-57-U17 P+	Chapel Hill, NC	1,364,126	2,379,267	3,791,263
2-42-U14 P+	Chapel Hill, NC	1,449,757	1,964,641	11,619,267

* Three different lots of rpilin were used as immunogen. Guinea pigs were immunized (s.c.) and bled as previously described. Pooled sera from week 6 bleed were assayed. Endpoint titers for week 0 sera were ≤ 250 . P+: pilliated cells. P-: non-pilliated variants derived from pilliated parental cells.

- 62 -

The whole cell ELISA analysis of mouse antisera against rpilin (Table 2) was done using microtiter plates in which the bacteria were dried down in the wells by the following protocol. Overnight agar cultures of bacteria were harvested into PBS with a Dacron swab and the turbidity of the suspension adjusted to an $A_{600} = 0.1$. Aliquots (100 μ L) of the bacterial suspension were added to the wells and the plate was air dried at 37°C. After evaporation of all the liquid, the plates were sealed and stored at 4°C until used. The remainder of the assay was done following the protocol previously described for the antigen ELISA of mouse antisera. The data from the whole cell ELISAs (Tables 2 and 3) suggest that rpilin induces antibodies which bind to conserved epitopes on the surface of piliated gonococci.

Example 15

Induction of a Mucosal Immune Response Against Gonococcal rpilin

Because gonorrhoea is a disease of the genital mucosae, it was of interest to examine the ability of mucosal immunization to induce a mucosal immune response. This was accomplished in the following manner. Mice were immunized intranasally with gonococcal rpilin in saline (1 or 10 μ g in 10 μ L) with or without 1 μ g of native cholera toxin on weeks 0, 1 and 2. Groups of five Swiss-Webster mice were immunized intranasally with rpilin with or without cholera toxin on weeks 0, 1 and 2. Analyses were conducted on pooled sera. Endpoints titers for week 0 were <50.

- 63 -

As shown in the following Table 4, there was a significant immune response detected in the antigen ELISA when the animals were immunized with rpilin in the absence of adjuvant (the week 0 titers were <300). This response was enhanced by the addition of native cholera toxin.

Table 4
Endpoint Titers for the Binding of Pooled Mouse Antisera Against Gonococcal rpilin to Purified Recombinant Gonococcal Pilin Protein

Antigen (dose µg)	Adjuvant (dose µg)	Day 22	Day 36	Day 50
rpilin (1)	none	1,684	1,287	2,291
rpilin (10)	none	29,046	20,658	71,067
rpilin (1)	cholera toxin (1)	4,673	7,526	3,273
rpilin (10)	cholera toxin (1)	107,011	321,714	280,079
None	cholera toxin (1)	<300	<300	<300

Next, these sera were examined for their ability to bind to intact, piliated gonococcal cells by an ELISA performed against cells from *N. gonorrhoeae* strain FA1090. The cells were dried down onto the microtiter plate as described previously. As shown in Table 5, a low titer was detected for rpilin alone (the week 0 titers were <300). The binding to piliated cells was greatly enhanced by addition of cholera toxin.

- 64 -

Table 5
Endpoint Titers for the Binding of Pooled Mouse
Antisera Against Gonococcal rpilin to Whole,
Piliated Gonococcal cells

5

Antigen (dose µg)	Adjuvant (dose µg)	Day 22	Day 36	Day 50
rpilin (1)	none	1,009	852	729
rpilin (10)	none	6,009	6,252	5,564
rpilin (1)	cholera toxin (1)	1,133	1,456	1,048
rpilin (10)	cholera toxin (1)	209,522	57,767	38,127
None	cholera toxin (1)	239	<500	<500

Example 16

Gonococcal Immunoelectron Microscopy

10

Visualization of the binding of antisera to piliated bacteria was conducted using the following protocol. Gold coated grids were spotted with an aliquot from a late log phase liquid culture of *recA*⁻ piliated *N. gonorrhoeae* for five minutes and the excess fluid was removed with a piece of filter paper. The grids were blocked with PBS-B for five minutes, followed by 1% (w/v) fish gelatin (Fluka, Ronkonkoma, NY) in PBS for 10 minutes. The grids were then incubated with polyclonal antisera diluted in PBS-B for 1-60 minutes at room temperature. Unbound antibodies were removed by floating the grid on droplets of PBS-B (4 x 30 seconds). The bound primary antibodies were detected by floating the grid on a drop of 12 nm colloidal gold bound to donkey anti-guinea pig IgG (Jackson Research Labs, West Grove, PA) diluted 1:5 in PBS-B for 30 minutes. The grids were then washed five

25

- 65 -

times on droplets of PBS-B as described above. The sample was then stabilized with 1% (v/v) glutaraldehyde (Electron Microscopy Sciences, Fort Washington, PA) in PBS for three minutes, then rinsed 5 x 1 minute in distilled water and lightly stained using NanoVan stain (NanoProbes, Stony Brook, NY) (pH 8) for 30 seconds. All liquid was removed by touching the grid to a piece of filter paper and examined on a Zeiss 10C transmission electron microscope at 15-75,000X using an acceleration voltage of 80 kv.

As shown by immunoelectron microscopy (Figure 1A), antibodies against the recombinant pilin were bound along the length of the heterologous pili filaments on the surface of gonococci. This suggested that the antibodies would bind to these epitopes which would be present on the surface of the bacteria *in vivo*.

Example 17

Whole Cell ELISA of Gonococcal rpilin Oligomer

In order to distinguish the biochemical and immunological properties of rpilin from those of intact pili (or pilin oligomer), purified rpilin was converted to rpilin oligomer by dialysis against pH 12 phosphate buffer. Antisera induced by this material (rpilin oligomer) was examined for its ability to bind to live, piliated gonococci using the whole cell ELISA. As shown in Table 6, antisera against rpilin oligomer had significantly lower endpoint titers for binding to diverse piliated gonococcal cells as compared to antisera induced by untreated rpilin. This suggests that rpilin oligomer had lost a significant number of the cross-reactive epitopes normally present on the rpilin protein.

- 66 -

Table 6
Effect of pH 12 ("oligomerization") on the Endpoint
Titers for rpilin Guinea Pig Antisera Binding to
Piliated *N. gonorrhoeae* Cells*

5

Strain	rpilin	rpilin Oligomer**
I-756	927,564	16,903
FA-19	107,100	1,982
FA1090 (2-57-U17)	721,786	6,737
LB2	905,711	4,205
#11	225,602	6,999
#4	288,120	8,104
3138K	106,315	5,429
T-1	497,987	42,162
1948	166,864	8,616
J474B	576,640	25,002

* Guinea pigs (4 per group) were immunized (s.c.) with
20 μ g of rpilin antigen adjuvanted with 25 μ g of
Stimulon™ QS-21 on weeks 0 and 4. Pooled sera from
week 6 were analyzed.

10

**Purified rpilin was dialyzed against 37 mM sodium
phosphate (pH 12) for 48 hours at 4°C, followed by
dialysis against PBS for 24 hours.

15

Example 18

Inhibition of Adherence to Human Cervical Cells

Because pili mediate the initial binding of
N. gonorrhoeae to human mucosal cells, the ability of
rpilin antibodies to inhibit the attachment of these

20

- 67 -

bacteria to epithelial cells was investigated. ME-180 cells, which were derived from a cervical carcinoma, were selected. In addition, to minimize the clumping of the piliated bacteria in these experiments, they were grown in liquid suspension cultures. This required using *recA*⁻ derivatives of gonococcal strains Pgh3-1 or I756 in order to maintain pili expression. These *recA*⁻ strains did not show significant clumping during the 4-5 hours growth in liquid culture, which made it easier to interpret the results.

In these experiments, an eight well chamber slide (Nunc) was seeded with ME-180 cells such that the cells were 80-90% confluent on the day of the experiment. An overnight culture of *recA*⁻ gonococcal cells was swabbed into PBS (warmed to 37°C) and used to inoculate a flask of liquid GC media supplemented with 0.4% (w/v) NaHCO₃ to a final A₆₀₀ = 0.2. The cell culture was incubated with shaking at 37°C at 120 RPM for approximately four hours, at which point the culture reached an A₆₀₀ ≅ 0.8. The bacterial cell suspension was diluted 1:8 in RPMI 1640. The wells of a second 8 well chamber were incubated for at least one hour with 300 μL of RPMI 1640 and fetal calf serum. The RPMI 1640 block was discarded and 40 μL of antisera or RPMI 1640 (without calf serum) added, followed by 260 μL of the diluted bacterial suspension (≈8x10⁷ CFU) and incubated for one hour at 37°C/5% (v/v)CO₂. The chamber well slide with the ME180 cells was washed once with RPMI 1640 devoid of antibiotics. Then, pre-incubated mixtures of bacteria and antisera were added onto the ME180 cells and the slides incubated for 30 minutes at 37°C. The media containing unbound bacterial cells was removed from the cervical cell monolayer and the wells washed gently three times with RPMI 1640. After the last wash, the chamber wells were

- 68 -

removed from the slide, the cells fixed in methanol for 30-60 seconds and stained with Wright-Giemsa stain (VWR Scientific, West Chester, PA). After destaining in water, coverslips were mounted over each well.

5 The slides were examined by light microscopy using oil immersion and pictures of representative views were taken by a person blinded as to the test sera. The resulting pictures were analyzed by persons who were also blinded as to the identity of the
10 samples. In addition, because the piliated gonococci bound the epithelial monolayers in clumps, the effect of antisera on the binding of the gonococcal cells was quantitated by counting clumps of bacteria instead of individual bacteria. The numbers of clumps of piliated
15 bacteria observed in ten random scans across each well were determined. The percent difference between wells containing immune and normal sera was determined. Again, this analysis was done independently by
20 researchers blinded as to the samples that they were analyzing.

 Initial results demonstrated that piliated and non-piliated cells had different binding patterns to the confluent monolayers of ME180 cells. Both piliated strains of gonococci typically bound as
25 bacterial clumps to selected epithelial cells within the confluent monolayer. In contrast, the corresponding isogenic non-piliated bacteria either did not bind (Pgh3-1) or showed a low level, disperse binding (I756) to the epithelial monolayer. Thus, the
30 aggregation of the bacteria on the epithelial monolayer correlated with the presence of pili.

 Next, the ability of guinea pig antisera against Pgh3-1 rpilin to inhibit the binding of piliated cells of strain I-756 to ME-180 cells was
35 tested. Analysis of representative pictures (compare

- 69 -

Figure 2A (week 6) to Figure 2B (week 0)) demonstrated that antibodies against rpilin significantly inhibited the binding of piliated gonococci to cervical epithelial cells. In contrast, the rpilin antisera had no effect on the binding of non-piliated cells from the same strain when compared to normal guinea pig sera (data not shown). While the number of bacteria bound under these conditions could not be determined, adherence was quantitated by counting the bacterial clumps bound in the presence of either normal or immune sera. Using this method, it was determined that antisera against rpilin resulted in $\approx 60\%$ decrease in the bacterial clumps bound to epithelial cells as compared with normal guinea pig serum.

While this assay did not yield readily quantifiable data, the estimates obtained by counting bacterial clumps probably resulted in an underestimation of the effectiveness of the antisera. This is because of the binding mediated by other cell surface components (e.g., Opa proteins) which would not be expected to be overcome with antisera against rpilin alone.

Example 19

Analytic Methods for Meningococcal Chimeric Class I rpilin

The analytic methods described in Example 10 were used for the chimeric meningococcal class I rpilin. As determined by MALDI-TOF mass spectroscopy, the subunit molecular weight of the meningococcal chimeric class I rpilin protein is 17,659 daltons, which is very similar to the anticipated mass of 17,676 daltons based on the amino acid content. When this protein was analyzed by size exclusion chromatography

- 70 -

using a Superose™ 12 column equilibrated in PBS containing 0.05% (w/v) Zwittergent™ 3-14, the chimeric class I rpilin has an apparent molecular weight of 69,480 daltons. This is essentially identical to the apparent molecular weight of gonococcal rpilin (68,899 daltons) analyzed under the same conditions.

The N-terminal sequence of the purified meningococcal class I rpilin protein was determined by Edman degradation and the results (from three different samples) agreed with the predicted protein sequence. At least 35 residues were determined for all sequences.

Example 20

Meningococcal Chimeric Class I rpilin ELISA

The endpoint titers against purified proteins or bacterial cells were determined by ELISA using the methods described in Examples 13 and 14. The ELISAs were performed using pooled sera from the respective bleeds. Whole cell ELISA was done on meningococcal cells which had been heat killed (56°C for 60 minutes) or dried down directly onto the microtiter plates. The cell suspension was diluted to an absorbance of 0.1 at 620 nm and 100 µL aliquots were placed into the wells of microtiter plates. Each plate was dried at 37°C or at room temperature, sealed and stored at 4°C until used. The protocol for the whole cell ELISA was modified as follows: (1) primary and secondary antisera were diluted in PBS containing 0.1% (v/v) Tween™-20 and 0.1% (w/v) BSA; and (2) the plates were washed five times with PBS containing 0.05% (v/v) Tween™-20 using a Skanwash 300 plate washer.

All the guinea pigs immunized with the chimeric class I rpilin responded very well, as demonstrated by the antigen ELISAs shown in Table 7.

- 71 -

Table 7
Endpoint Titers for the Binding of Meningococcal
Chimeric Class I rpilin Antisera to Purified
Meningococcal Chimeric Class I rpilin*

Adjuvant:

Bleed:	Stimulon™ QS-21	AlPO ₄	None
Week 0	23	12	32
Week 4	26,607	12,067	4,829
Week 6	1,519,956	372,539	302,911

* Guinea pigs (four per group) were immunized (s.c.) on weeks 0 and 4 with 20 µg of chimeric class I rpilin adjuvanted with (a) 25 µg of Stimulon™ QS-21 in PBS (pH6); (b) 100 µg of AlPO₄ in saline; or (c) PBS (pH7) only. The animals were bled on weeks 0, 4 and 6. Pooled sera was used for all analyses.

Significant responses were also seen with the ELISAs to piliated cells, as shown in Table 8.

Table 8
Endpoint Titers for the Binding of Meningococcal
Chimeric Class I rpilin Antisera to Piliated Cells from
N. meningitidis (strain H355)*

Adjuvant:

Bleed:	Stimulon™ QS-21	AlPO ₄	None
Week 0	28	19	53
Week 4	1,293	1,052	381
Week 6	61,497	25,477	16,467

* Cells were heat killed.

Effects of Adjuvants on Immune Response

5

The effect of adjuvants upon the immune response against the meningococcal chimeric class I rpilin was studied in mice using the methods described in Example 13. As shown in Table 9, the most significant response for the binding of antisera with the meningococcal chimeric class I rpilin was achieved with the addition of Stimulon™ QS-21.

10

Table 9

15

Endpoint Titers for the Binding of Meningococcal Chimeric Class I rpilin Antisera to Purified Meningococcal Chimeric Class I rpilin*

Adjuvant:

Bleed:	Stimulon™ QS-21	AlPO ₄	MPL™	AlPO ₄ /MPL™	None
Week 0	<50	44	<50	31	<50
Week 4	44,011	29,925	40,146	110,093	<250
Week 6	707,084	103,437	284,455	137,686	115,022

20

* Mice (ten per group) were immunized (s.c.) on weeks 0 and 4 with 10 µg of meningococcal chimeric class I rpilin adjuvanted with (a) 25 µg of Stimulon™ QS-21 in PBS (pH 6); (b) 100 µg of AlPO₄ in saline; (c) 50 µg MPL™ in PBS (pH 7); (d) 100 µg of AlPO₄ and 50 µg MPL™ in saline; or (e) PBS (pH 7) only. The animals were bled on weeks 0, 4 and 6. Pooled sera was used for all analyses.

25

- 73 -

As shown in Table 10, the most significant response for the binding of antisera to piliated cells from *N. meningitidis* was also achieved with the addition of Stimulon™ QS-21.

5

Table 10

Endpoint Titers for the Binding of Meningococcal Chimeric Class I rpilin Antisera to Piliated Cells from *N. meningitidis* (strain H355)*

10

Adjuvant

Bleed:	Stimulon™ QS-21	AlPO ₄	MPL™	AlPO ₄ /MPL™	None
Week 0	172	146	153	160	<50
Week 4	6,088	2,310	4,205	5,647	311
Week 6	171,718	25,135	52,053	17,039	16,617

* Cells were heat killed.

15

Further analyses demonstrated that this antisera against the chimeric class I rpilin bound to meningococcal cells which expressed either class I pilin or, in some cases, class II pilin. The results, shown in Table 11, evidence this partial cross-reactivity.

20

25

30

- 74 -

Endpoint Titers for the Binding of Meningococcal
Chimeric Class I rpilin Antisera to Piliated Cells from
*N. meningitidis**

5

Adjuvant

Strain	Class Pilin expressed	Day 0	Stimulon™ QS-21	AlPO ₄	MPL™
H355	I	409	127,383	41,190	102,987
M982	I	217	>36,540	>36,540	>36,540
CDC1521	II	988	2,602	1,345	1,768
FAM18	II	3,518	>36,540	26,513	>36,540

* Cells were dried down (at room temperature) directly onto microtiter plates without being heat killed.

10

Example 21

Meningococcal Chimeric Class I rpilin
Immunoelectron Microscopy

15

20

25

Visualization of the binding of chimeric meningococcal class I rpilin antisera to piliated cells from *N. meningitidis* strain H355 was conducted using transmission-electron microscopy as follows. A colony from an overnight culture of *N. meningitidis* was carefully picked up using a sterile loop and placed in a microfuge tube containing 0.5-1.0 mL of modified Franz media [1.3 g/L glutamic acid, 20 mg/L cysteine, 10 g/L Na₂HPO₄·7H₂O, 90 mg/L KCl, 6 g/L NaCl, 2 g/L yeast dialysate and supplemented with dextrose (4 g/L), glutamic acid (100 mg/L), cocarboxylase (200 µg/L) and ferric nitrate (5 mg/L)]. Gold coated grids were spotted with an aliquot of the cell suspension for five

- 75 -

spotted with an aliquot of the cell suspension for five minutes and the excess fluid was removed with a piece of filter paper. The bacterial cells were then fixed with 4% (v/v) paraformaldehyde, 0.1% (v/v) glutaraldehyde in PBS for 30 minutes at room temperature. The grids were incubated, in sequence, with (a) PBS-B for five minutes, (b) 1% (w/v) fish gelatin in PBS for 10 minutes, and (c) PBS containing 0.2 M glycine for five minutes. The blocked grids were then probed with antisera against meningococcal chimeric class I rpilin protein as described in Example 16. As shown in Figure 3A), the antibodies against the meningococcal chimeric class I rpilin protein bound along the length of the pili. In contrast, normal serum (week 0) did not show any binding to the pili (Figure 3B).

Example 22

Cross-reactivity of Meningococcal Chimeric Class I rpilin Antisera with Gonococcal Piliated Cells

Based on the sequence similarity of meningococcal class I pilin and gonococcal pilin, it was shown in Example 4 above that antisera directed against gonococcal rpilin recognized and bound to piliated meningococcal cells. In this example, it is demonstrated that antisera raised against meningococcal chimeric class I rpilin binds to piliated gonococcal cells. The data from the mouse and guinea pig experiments are summarized in Tables 12 and 13, respectively.

35

Table 12
 Endpoint Titers for the Binding of Mouse Antisera
 Against Meningococcal Chimeric Class I rpilin to
 Piliated *N. gonorrhoeae* Cells

5

Antigen / Adjuvant

GC Strain	Nm rclass I pilin					GC rpilin + MPL™
	Stimulon™ QS-21	AlPO ₄	MPL™	AlPO ₄ / MPL™	None	
I756	4,527,943	79,927	114,958	56,627	57,426	356,936
FA1090	531,627	40,406	97,224	31,267	38,122	219,600

10

Table 13
 Endpoint Titers for the Binding of Guinea Pig Antisera
 Against Meningococcal Chimeric Class I rpilin to
 Piliated *N. gonorrhoeae* Cells

Antigen / Adjuvant

GC Strain	Nm rclass I pilin			GC rpilin + Stimulon™ QS-21
	Stimulon™ QS-21	AlPO ₄	None	
I756	301,969	122,714	78,111	46,424
FA1090	322,311	262,422	170,842	108,094

15

GC - *N. gonorrhoeae*; Nm - *N. meningitidis*

20

- 77 -

Example 23Passive Protection Against Meningococcal Bacteremia
by Meningococcal Chimeric Class I rpilin Antisera

5

10

15

20

25

30

35

An accepted animal model for evaluating the ability of vaccines to protect against meningococcal bacteremia is the infant rat model originally described by Saukkonen and Leinonen (34). The ability of guinea pig antisera against meningococcal chimeric class I rpilin (adjuvanted with Stimulon™ QS-21) to protect against bacteremia caused by a meningococcal strain, which expresses a pilin, was tested. On day 0, Sprague-Dawley infant rats (4-5 days old) were passively immunized (i.p.) with 0.1 mL of guinea pig antiserum (week 6) against chimeric class I rpilin diluted 1:5, 1:10 or 1:20 in PBS. The control group received 0.1 mL injection of normal guinea pig serum (week 0) diluted 1:5 in PBS. Twenty-four hours later, the animals were challenged i.p. with approximately 5×10^5 colony forming units (cfu) in 0.1 mL of piliated *N. meningitidis* (strain H355). Three hours after challenge, the animals were sacrificed and aliquots of cardiac blood were diluted and plated onto GC agar plates. The plates were then incubated for 18-24 hours at 37°C with 5% CO₂. The bacterial colonies were counted and the level of bacteremia was then determined. One way analysis of variance t test was used to compare groups receiving immune serum (week 6) with the control group receiving normal serum (week 0). As shown in Table 14 below, animals passively immunized with guinea pig antiserum specific for meningococcal chimeric class I rpilin showed more than a log reduction in the level of bacteremia as compared to those animals immunized with normal guinea pig serum.

- 78 -

This difference was statistically significant, with a p value of <0.05.

Table 14

5 Ability of Guinea Pig Antisera Against Meningococcal
Chimeric Class I rpilin Protein to
Prevent Bacteremia in Infant Rats Challenged with
Piliated *N. meningitidis* (Strain H355)*

Bleed	Dilution	Mean cfu \pm std
Week 0	1:5	4.87 \pm 0.18
Week 6	1:5	3.55 \pm 0.48**
Week 6	1:10	3.63 \pm 0.36**
Week 6	1:20	3.98 \pm 0.75**

10 * Antisera against meningococcal chimeric class I
rpilin protein was obtained from guinea pigs as
described in Table 7.

** p <0.05.

15 cfu \pm std = colony forming units \pm standard deviation.

Example 24

Induction of a Mucosal Immune Response Against
Meningococcal Chimeric Class I rpilin

20 Mice were immunized intranasally with
meningococcal chimeric class I rpilin in saline (5 μ g
in 10 μ L) with or without 1 μ g of a cross-reactive
mutant form of cholera toxin (CT-CRM, E29H) on weeks 0,
25 1 and 2. As shown in the following Table 15, there was
a significant immune response detected in the antigen
ELISA when the animals were immunized with rpilin in
the absence of adjuvant. This response was enhanced by
the addition of cholera toxin.

30

- 79 -

Table 15

5 Endpoint Titers for the Binding of Pooled Mouse
Antisera Against Meningococcal Chimeric Class I rpilin
to Purified Recombinant Meningococcal Chimeric Class I
rpilin Protein*

	rpilin, no adjuvant	rpilin plus CT-CRM
<u>Sera</u>		
IgG	6,168	1,181,871
IgA	490	3,940
<u>Bronchial wash**</u>		
IgG	<10	580
IgA	<10	19
<u>Nasal wash**</u>		
IgG	<10	98
IgA	12	236
<u>Vaginal wash**</u>		
IgG	174	70
IgA	15	687

10 * Pooled sera from week 4 were analyzed. Endpoint
titers for pooled sera from week 0 for IgG and IgA were
<50.

** Washes were performed as follows:

15 Bronchial: Lungs were washed 5 times with 1 mL
RPMI 1640, then 50 μ L fetal bovine serum (FBS) was then
added to the sample, which was clarified by

- 80 -

centrifugation (12,000 x g x 5 minutes) and stored at -20°C.

Nasal: The nasal passages were washed once with 0.5 mL of RPMI 1640 and 20 µL of FBS was then added to the sample before storage at -20°C.

Vaginal: Vaginas were washed 5 times with 0.075 mL of RPMI 1640 and 10 µL of FBS was then added to the sample before storage at -20°C.

Example 25

Active Protection Against Meningococcal Colonization by Meningococcal Chimeric Class I rpilin Antisera

The initial step in meningococcal disease in human beings is the colonization of the nasopharynx by the bacteria. In this process, pili are believed to play a major role in mediating the initial attachment to the epithelial cells. A number of researchers have described procedures for colonizing the nasopharynx in neonatal animals, but no one has investigated this as a model for testing the efficacy of meningococcal vaccines (35). In order to assess the invention described herein, a nasal colonization model for *N. meningitidis* using adult outbred mice has been developed. Swiss-Webster mice were immunized with meningococcal chimeric class I rpilin adjuvanted with MPL™ subcutaneously on weeks 0, 4 and 8. At week 10, the animals received an intraperitoneal injection of 2 mg iron dextran (Sigma) and were challenged intranasally with approximately 1×10^7 cfu of mid-log phase piliated meningococci in a volume of 10 µL which also contained 40 µg of iron dextran. On day 1 after challenge, half the animals received an additional intraperitoneal injection of 2 mg iron dextran. The

- 81 -

number of viable bacteria in the nose were determined on days 1 and 2 after challenge by plating nasal tissue homogenates on GC agar plates containing selective antibiotics. The results are shown in Table 16.

5

Table 16

Number of Viable Bacteria (cfu) Recovered from Nasal Homogenates of Mice Challenged with Piliated *N. meningitidis* Strain H355*

10

Antigen (Dose µg)*	cfu per nose	
	Day 1**	Day 2**
H355 Whole cell (25)	1,165	67
Class I rpilin (10)	6,866	63
Saline	17,943	3,406

* All vaccines were formulated with 100 µg of MPL™ per dose. Each group consisted of five mice.

** Days after intranasal challenge.

15

Example 26

Western Blot Analysis of the Immune Response Against Meningococcal Class II Chimeric rpilin

20

The purified meningococcal class II chimeric rpilin was used to immunize guinea pigs following the protocol described in Example 11. The antisera derived from guinea pigs immunized with meningococcal class II chimeric rpilin were analyzed first by Western blots (data not shown). These blots demonstrated that the antisera against meningococcal class II chimeric rpilin recognized a band corresponding to pilin in whole cell lysate from piliated meningococcal cells which expressed either class II pilin (FAM18) or class I pilin (H355). In contrast, antisera directed against

30

- 82 -

an extract from *E. coli* containing the pTrcHis vector only did not react with either pilin band in these Western blots.

5

Example 27

Binding of Antisera against Meningococcal Chimeric Class II rpilin to Piliated Meningococcal Cells

10

Antisera elicited against partially purified meningococcal chimeric class II rpilin was shown to bind to meningococcal cells from the homologous strain, FAM18 with a titer of >36,450 (the week 0 titer was 473).

15

Bibliography

1. Tennent, J.M., and Mattick, J.S., pages 127-146 of Fimbriae. Adhesion, genetics, biogenesis and vaccines, P. Klemm, Ed. (CRC Press, Boca Raton, FL 1994).
2. Strom, M.S., and Lory, S., Ann. Rev. Microbiol., 47, 565-596 (1993).
3. Heckels, J.E., Clin. Microbiol. Rev., 2 (Suppl.), S66-73 (1989).
4. U.S. Patent Number 4,702,911.
5. Schoolnik, G.K., J. Exp. Med., 159, 1351-1370 (1984).
6. Davies, J.K., et al., pages 147-155 of Fimbriae. Adhesion, genetics, biogenesis and vaccines, P. Klemm, Ed. (CRC Press, Boca Raton, FL 1994).
7. Aho, E.L., et al., Infect. Immun., 65, 2613-2620 (1997).
8. Achtman, M., et al., J. Inf. Dis., 165, 53-68 (1992).
9. Levine, M.M., et al., pages 255-270 of Fimbriae. Adhesion, genetics, biogenesis and vaccines, P. Klemm, Ed. (CRC Press, Boca Raton, FL 1994).
10. Stewart, D.J., et al., Aust. Vet. J., 62, 153-159 (1985).
11. Tramont, E.C., Clin. Microbiol. Rev., 2 (Suppl.), S74-7 (1989).
12. Boslego, J.W., et al., Vaccine, 9, 154-162 (1991).
13. Rothbard, J.B., and Schoolnik, G.K., Adv. Exp. Med. Biol., 185, 247-73 (1985).
14. Olafson, R.W., et al., Infect. Immun., 48, 336-342 (1985).
15. Seifert, H.S., et al., Vaccine, 6, 107-109 (1988).

16. Sparling, P.F., et al., Proc. Natl. Acad. Sci. USA, 91, 2456-2463 (1994).
17. Rothbard, J.B., et al., Proc. Natl. Acad. Sci. USA, 82, 915-919 (1985).
18. Forest, K.T., and Tainer, J.A., pages 167-173 of Vaccines 97. Molecular Approaches to the Control of Infectious Diseases, F. Brown, et al., Eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1997).
19. Robinson, E.N.J., et al., Mol. Microbiol., 3, 57-64 (1989).
20. Eisentein, B.I., et al., pages 89-113 of Recombinant DNA vaccines: rationale and stratagies, R.E. Isaacson, Ed., (Marcel Dekker, Inc., New York, NY 1992).
21. Lepper, A.W., Aust. Vet. J., 65, 310-316 (1988).
22. Hull, R.A., et al., Infec. Immun., 33, 933-938 (1981).
23. Granted European Patent Number 202,260 B1.
24. Hoyne, P.A., et al., J. Bact., 174, 7321-7327 (1992).
25. Elleman, T.C., et al., Infect. Immun., 51, 187-192 (1986).
26. O'Meara, T.J., et al., Immun. Cell. Biol., 71, 473-488 (1993).
27. Emery, D.L., et al., Aust. Vet. J., 61, 237-8 (1984).
28. Stewart, D.J., et al., Vet. Microbiol., 27, 283-93 (1991).
29. Alves, A.M.B., et al., American Society for Microbiology, Abstract E-79, page 253 (1997).
30. Meyer, T.F., et al., Cell, 30, 45-52 (1982).

31. Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).
32. Stephens, D.S., Clin. Microbiol. Rev., 2 (Suppl.), S104-111 (1989).
33. Tramont, E.C., et al., J. Clin. Invest., 68, 881-888 (1981).
34. Saukkonen, K. and Leinonen, M., pages 815-820 of Gonococci and Meningococci, J. T. Poolman, Ed. (Kluwer Academic Publications, Dordrecht, Netherlands, 1986).
35. Salit, I.E., et al., Can. J. Microbiol., 30, 1022-1029 (1984).

- 86 -

What is claimed is:

1. A vaccine composition comprising an isolated and purified recombinantly-expressed pilin protein of the genus *Neisseria*, wherein said vaccine composition elicits a protective immune response in a human host.
2. The vaccine composition of Claim 1 where the pilin protein is from the species *Neisseria gonorrhoeae*.
3. The vaccine composition of Claim 1 where the pilin protein is from the species *Neisseria meningitidis*.
4. The vaccine composition of Claim 3 where the pilin protein is the class I pilin protein of *Neisseria meningitidis*.
5. The vaccine composition of Claim 3 where the pilin protein is the class II pilin protein of *Neisseria meningitidis*.
6. The vaccine composition of Claim 1 where the pilin protein is a chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class I *Neisseria meningitidis* having the amino acid sequence of amino acids 1-167 of SEQ ID NO:2 prior to processing or having the amino acid sequence of amino acids 8-167 of SEQ ID NO:2 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.
7. The vaccine composition of Claim 1 which further comprises an adjuvant, diluent or carrier.
8. The vaccine composition of Claim 7 wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, Stimulon™ QS-21, 3-O-deacylated monophosphoryl lipid A, IL-12 and wild-type or mutant cholera toxin.

- 87 -

9. A method of immunizing against *Neisseria gonorrhoeae* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 2.

10. A method of immunizing against *Neisseria gonorrhoeae* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 3.

11. A method of immunizing against *Neisseria gonorrhoeae* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 6.

12. A method of immunizing against *Neisseria meningitidis* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 3.

13. A method of immunizing against *Neisseria meningitidis* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 2.

14. A method of immunizing against *Neisseria meningitidis* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 6.

15. A method for preparing a vaccine composition which comprises including an isolated and purified recombinantly-expressed pilin protein of the genus *Neisseria*, in an amount sufficient such that said vaccine composition elicits a protective immune response in a human host.

16. An isolated and purified DNA sequence comprising a DNA sequence which hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence encoding the chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and

class I *Neisseria meningitidis* having the amino acid sequence of amino acids 1-167 of SEQ ID NO:2 prior to processing or having the amino acid sequence of amino acids 8-167 of SEQ ID NO:2 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

17. The isolated and purified DNA sequence of Claim 16, wherein said DNA sequence hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence having the nucleotide sequence of nucleotides 1-501 or 22-501 of SEQ ID NO:1.

18. An isolated and purified DNA sequence comprising a DNA sequence encoding the chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class I *Neisseria meningitidis* having the amino acid sequence of amino acids 1-167 of SEQ ID NO:2 prior to processing or having the amino acid sequence of amino acids 8-167 of SEQ ID NO:2 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

19. A plasmid containing an isolated and purified DNA sequence comprising a DNA sequence which hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence encoding the chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class I *Neisseria meningitidis* having the amino acid sequence of amino acids 1-167 of SEQ ID NO:2 prior to processing or having the amino acid sequence of amino acids 8-167 of SEQ ID NO:2 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

20. The plasmid of Claim 19 wherein the plasmid contains a DNA sequence which hybridizes under standard high stringency Southern hybridization

- 89 -

conditions with a DNA sequence having the nucleotide sequence of nucleotides 1-501 or 22-501 of SEQ ID NO:1.

21. A plasmid containing an isolated and purified DNA sequence encoding a chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class I *Neisseria meningitidis* comprising the DNA sequence of Claim 18.

22. The plasmid of Claim 21 wherein the plasmid is that designated pPX2004 (ATCC 98637).

23. A host cell transformed with the plasmid of Claim 19.

24. The host cell of Claim 23 wherein the host cell is an *Escherichia coli* strain.

25. The host cell of Claim 24 wherein the plasmid is that designated pPX2004 (ATCC 98637).

26. A method of producing a chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class I *Neisseria meningitidis* which comprises transforming or transfecting a host cell with the plasmid of Claim 19 and culturing the host cell under conditions which permit the expression of said chimeric recombinant pilin protein by the host cell.

27. An isolated and purified chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class I *Neisseria meningitidis* having the amino acid sequence of amino acids 1-167 of SEQ ID NO:2 prior to processing or having the amino acid sequence of amino acids 8-167 of SEQ ID NO:2 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

28. The vaccine composition of Claim 1 where the pilin protein is a chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* having the amino acid sequence of amino acids 1-170 of SEQ ID NO:4 prior to processing or

having the amino acid sequence of amino acids 8-170 of SEQ ID NO:4 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

29. A method of immunizing against *Neisseria gonorrhoeae* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 28.

30. A method of immunizing against *Neisseria meningitidis* which comprises administering to a human host an immunogenic amount of the vaccine composition of Claim 28.

31. An isolated and purified DNA sequence comprising a DNA sequence which hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence encoding the chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* having the amino acid sequence of amino acids 1-170 of SEQ ID NO:4 prior to processing or having the amino acid sequence of amino acids 8-170 of SEQ ID NO:4 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

32. The isolated and purified DNA sequence of Claim 31, wherein said DNA sequence hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence having the nucleotide sequence of nucleotides 1-510 or 22-510 of SEQ ID NO:3.

33. An isolated and purified DNA sequence comprising a DNA sequence encoding the chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* having the amino acid sequence of amino acids 1-170 of SEQ ID NO:4 prior to processing or having the amino acid sequence of amino acids 8-170 of SEQ ID NO:4 after processing to a mature

- 91 -

protein, or a biologically equivalent amino acid sequence thereof.

34. A plasmid containing an isolated and purified DNA sequence comprising a DNA sequence which hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence encoding the chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* having the amino acid sequence of amino acids 1-170 of SEQ ID NO:4 prior to processing or having the amino acid sequence of amino acids 8-170 of SEQ ID NO:4 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

35. The plasmid of Claim 34 wherein the plasmid contains a DNA sequence which hybridizes under standard high stringency Southern hybridization conditions with a DNA sequence having the nucleotide sequence of nucleotides 1-510 or 22-510 of SEQ ID NO:3.

36. A plasmid containing an isolated and purified DNA sequence encoding a chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* comprising the DNA sequence of Claim 33.

37. The plasmid of Claim 36 wherein the plasmid is that designated pPX8017 (ATCC 207199).

38. A host cell transformed with the plasmid of Claim 34.

39. The host cell of Claim 38 wherein the host cell is an *Escherichia coli* strain.

40. The host cell of Claim 39 wherein the plasmid is that designated pPX8017 (ATCC 207199).

41. A method of producing a chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* which comprises transforming or transfecting a host cell with the

- 92 -

plasmid of Claim 34 and culturing the host cell under conditions which permit the expression of said chimeric recombinant pilin protein by the host cell.

42. An isolated and purified chimeric recombinant pilin protein of *Neisseria gonorrhoeae* and class II *Neisseria meningitidis* having the amino acid sequence of amino acids 1-170 of SEQ ID NO:4 prior to processing or having the amino acid sequence of amino acids 8-170 of SEQ ID NO:4 after processing to a mature protein, or a biologically equivalent amino acid sequence thereof.

1/8




FIG.1A




FIG. 1B

3/8



FIG. 1C

4/8




FIG.2A

5/8




FIG.2B

6/8



FIG.3A

7/8




FIG.3B

8/8




FIG.3C

SEQUENCE LISTING

<110> American Cyanamid Company

<120> Vaccines Containing Recombinant Pilin Against Neisseria
Gonorrhoeae or Neisseria Meningitidis

<130> 33377-00/PCT

<140>

<141>

<160> 24

<170> PatentIn Ver. 2.0

<210> 1

<211> 504

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Chimeric of
Neisseria Meningitidis Class I and Neisseria
Gonorrhoeae

<220>

<221> CDS

<222> (1)..(501)

<400> 1

atg gat acc ctt caa aaa ggc ttt acc ctt atc gag ctg atg att gtg	48
Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val	
1 5 10 15	
atc gcc atc gtc ggc att ttg gcg gca gtc gcc ctt ccc gcc tac caa	96
Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln	
20 25 30	
gac tac acc gcc cgc gcg caa gtt tcc gaa gcc atc ctt ttg gcc gaa	144
Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu	
35 40 45	
ggt caa aaa tca gcc gtt acc gag tat tac ctg aat cac ggc gaa tgg	192
Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp	
50 55 60	
ccc ggc aac aac act tct gcc ggc gtg gca tct tct tca aca atc aaa	240

Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys
 65 70 75 80

ggc aaa tat gtt aag gaa gtt aca gtc gca aac ggc gtc att acc gcc 288
 Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala
 85 90 95

aca atg ctt tca agc ggc gta aac aaa gaa atc caa ggc aaa aaa ctc 336
 Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
 100 105 110

tcc ctg tgg gcc aag cgt caa gac ggt tgc gta aaa tgg ttc tgc gga 384
 Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly
 115 120 125

cag ccg gtt acg cgc acc gac gcc aaa gcc gac acc gtc gcc gcc gcc 432
 Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
 130 135 140

gcc aag acc gcc gac aac atc aac acc aag cac ctg ccg tca acc tgc 480
 Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
 145 150 155 160

cgc gac gca agt gat gcc agc taa 504
 Arg Asp Ala Ser Asp Ala Ser
 165

<210> 2
 <211> 167
 <212> PRT
 <213> Artificial Sequence

<400> 2
 Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
 1 5 10 15

Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
 20 25 30

Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu
 35 40 45

Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp
 50 55 60

Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys
 65 70 75 80

Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala
 85 90 95

Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
 100 105 110

Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly
 115 120 125

Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
 130 135 140

Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
 145 150 155 160

Arg Asp Ala Ser Asp Ala Ser
 165

<210> 3
 <211> 510
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:Chimeric of
 Neisseria Meningitidis Class II and Neisseria
 Gonorrhoeae

<220>
 <221> CDS
 <222> (1)..(510)

<400> 3
 atg gaa gca atc caa aaa ggt ttc acc ctg atc gag ctg atg atc gtc 48
 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
 1 5 10 15

atc gcc atc gtc ggt atc ttg gca gcc gtc gcc ctg ccc gca tac caa 96
 Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
 20 25 30

gac tac acc gcg cgc gcc caa atg tcc gaa gcc ctg act ttg gca gaa 144
 Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
 35 40 45

ggt caa aaa tcc gca gtg atc gag tat tat tcc gac aac ggc aca ttc 192

Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Asn Gly Thr Phe
 50 55 60

ccg aac agc aat act tcc gca ggt att gct gcc tct aac gag att aaa 240
 Pro Asn Ser Asn Thr Ser Ala Gly Ile Ala Ala Ser Asn Glu Ile Lys
 65 70 75 80

ggt aag tat gtg gca tcg gtt aag gtt gaa ggt aat gcc tct gtt gct 288
 Gly Lys Tyr Val Ala Ser Val Lys Val Glu Gly Asn Ala Ser Val Ala
 85 90 95

tct att acc gct acc atg aac tct agt aat gtg aat aag gac atc aaa 336
 Ser Ile Thr Ala Thr Met Asn Ser Ser Asn Val Asn Lys Asp Ile Lys
 100 105 110

ggt aaa acc ttg gta ctc gtc ggc aaa caa aac tcc ggt tcg gta aaa 384
 Gly Lys Thr Leu Val Leu Val Gly Lys Gln Asn Ser Gly Ser Val Lys
 115 120 125

tgg ttc tgc gga cag ccg gtt acg cgc gac aac gcc gac aac gac gac 432
 Trp Phe Cys Gly Gln Pro Val Thr Arg Asp Asn Ala Asp Asn Asp Asp
 130 135 140

gtc aaa gac gcc ggc aac aac ggc atc gaa acc aag cac ctg ccg tca 480
 Val Lys Asp Ala Gly Asn Asn Gly Ile Glu Thr Lys His Leu Pro Ser
 145 150 155 160

acc tgc cgc gat acg tca tct gat gcc aaa 510
 Thr Cys Arg Asp Thr Ser Ser Asp Ala Lys
 165 170

<210> 4
 <211> 170
 <212> PRT
 <213> Artificial Sequence

<400> 4
 Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
 1 5 10 15

Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
 20 25 30

Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
 35 40 45

Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Asn Gly Thr Phe

ggctctagac tgtcagacca agtttactc 29

<210> 8
<211> 27
<212> DNA
<213> Neisseria gonorrhoeae

<400> 8
ggctctagat tgaagcattt atcaggg 27

<210> 9
<211> 28
<212> DNA
<213> Neisseria gonorrhoeae

<400> 9
ggctctagat aaacagtaat acaagggg 28

<210> 10
<211> 28
<212> DNA
<213> Neisseria gonorrhoeae

<400> 10
ggctctagat tagaaaaact catcgagc 28

<210> 11
<211> 36
<212> DNA
<213> Neisseria Meningitidis Class I

<400> 11
ccccgcgcca tggacaccct tcaaaaaggt ttacc 36

<210> 12
<211> 39
<212> DNA
<213> Neisseria Meningitidis Class I

<400> 12
gggcctggat ccgagtggcc gtggaaaatc acttaccgc 39

<210> 13
 <211> 31
 <212> DNA
 <213> Neisseria Meningitidis Class I

 <400> 13
 ccggcgcgctc tctcacggcg aatggcccgg c 31

<210> 14
 <211> 39
 <212> DNA
 <213> Neisseria Meningitidis Class I

 <400> 14
 gggcctggat ccgagtggcc gtggaaaatc acttaccgc 39

<210> 15
 <211> 25
 <212> DNA
 <213> Neisseria gonorrhoeae

 <400> 15
 gcataattcg tgtcgctcaa ggcgc 25

<210> 16
 <211> 34
 <212> DNA
 <213> Neisseria gonorrhoeae

 <400> 16
 gccgcgcgctc tcccgtgatt caggtaatac tcgg 34

<210> 17
 <211> 25
 <212> DNA
 <213> Neisseria Meningitidis Class I

 <400> 17
 gcataattcg tgtcgctcaa ggcgc 25

<210> 18
 <211> 39
 <212> DNA

<213> Neisseria Meningitidis Class I

<400> 18

gggcctggat ccgagtggcc gtggaaaatc acttaccgc

39

<210> 19

<211> 37

<212> DNA

<213> Neisseria Meningitidis Class II

<400> 19

gcggccgcca tggaagcaat ccaaaaaggt ttcaccc

37

<210> 20

<211> 33

<212> DNA

<213> Neisseria Meningitidis Class II

<400> 20

gccgcgcgctc tccgaaccgg agttttgttt gcc

33

<210> 21

<211> 33

<212> DNA

<213> Neisseria gonorrhoeae

<400> 21

ccgggccgctc tcggttcggt aaaatggttc tgc

33

<210> 22

<211> 30

<212> DNA

<213> Neisseria gonorrhoeae

<400> 22

gggcctggat ccgtgggaaa tcacttaccg

30

<210> 23

<211> 37

<212> DNA

<213> Neisseria Meningitidis Class II

<400> 23

